![Page 1: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/1.jpg)
1
IND1279210003VersionMay15,2017170515ProtocolTAADRCT
Title:TumescentAnesthesiaAntibioticDelivery(TAAD)andSubQKathforPreventionofSurgicalSiteInfection,ThrombosisandSepsis.WIRBProtocol#pendingFDAINDapprovalClient’sIdentifyingNumber:TAADClinicaltrials.govRegistration#pendingFDAINDapprovalSponsor:JeffreyA.Klein,MD,MPHPrincipalClinicalInvestigator:JeffreyA.Klein,MD,MPH
ClinicalProfessor,DepartmentofDermatology,UniversityofCalifornia,IrvinePrincipalStatisticalInvestigator:DanielJeske,PhD
Professor&Chair,DepartmentofStatistics,UniversityofCalifornia,RiversideClinicalTrialCoordinator:TobedeterminedStatisticalDesignandAnalysis:StatisticalCollaboratory,UCRiverside
DepartmentofStatistics,UniversityofCalifornia,RiversideContact:JeffreyAlanKlein,MD,MPH
30280RanchoViejoRoad,SanJuanCapistrano,CA92675OfficeHoursTel:949-248-1632Fax949-248-0507 AfterHoursCellPhone:[email protected]
FinancialDisclosure:JeffreyKlein,MDhasseveralUSPatentsondevicesfortumescentlocalanesthesia,tumescentanesthesiaantibioticdelivery(TAAD)andtumescentplateletinhibition.Dr.Klein’swife,KathleenHuttonKlein,MD,hasanownershipinterestinHKSurgical,Inc.,whichmarketsdevicesfortumescentlocalanesthesiaandDrugsunderConsideration:cefazolin,metronidazole,ertapenem,lidocaine,epinephrine.Possiblyertapenemandotherappropriateantibiotics.Therewillbemorethanoneormoreresearchsite(s).
![Page 2: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/2.jpg)
2
ii. PurposeofStudyandBackgroundA.Objectivesandpurposeofthepresentstudy.
Despitetheuseofmultipleinterventions,surgicalsiteinfection(SSI)continuestobeasignificantproblem.Thereisaneedforaneffective,accessible,inexpensive,simple,safetechniquethatreducestheriskofSSI.Intravenousantibioticdelivery(IVAD)usinganover-the-needleintravenous(IV)catheteristhecurrentstandardmodeofantibioticdeliveryforSSIprevention.
1)Subcutaneousdeliveryofanantibioticssuchascefazolinandmetronidazoleisoff-label.
2)Subcutaneousinfiltrationofdiluteatumescentlidocainesolution(withorwithoutantibiotics)atlidocainedosagesthatexceed7mg/kgisoff-label.3)Subcutaneousinfiltrationofdiluteantibiotic(s)inatumescentlidocainesolutionusinganovelover-the-needlesubcutaneouscatheter(SubQKath)requiresFDA510(k)approval.
Thismulticenterrandomizedclinicaltrial(RCT)protocolisdesignedto1)comparetwomodesofantibioticdelivery,2)validatethesafetyoftumescentlidocaineatdosagesupto28mg/kg,3)validatethesafetyoftheSubQKathfortumescentanestheticantibioticdelivery(TAAD).4)Thisprotocolisnotaclinicaltrialcomparingtheeffectsofdifferentdrugs.5)ThisRCTcomparesIVADaloneversusconcomitantTAADandIVAD(TAAD+IVAD).TAADusinganovelover-the-needlesubcutaneouscatheter(SubQKath)bydirectsubcutaneous
infiltrationofdiluteantibiotic(s)inatumescentlidocainesolutionisanovelmodeofantibioticdelivery.Thisprotocoldescribesanopenlabelrandomizedclinicaltrial(RCT)withprospective
multicentermeta-analyticstatisticaldesignusingsequentialdataanalysiswithonestoppingpoint.Wehypothesizethat,comparedtoIVADalone,TAAD+IVADwillbesuperiorintermsofreducing
theriskofSSI,aswellasvenousthromboembolism(VTE)andsystemicinflammatoryresponsesyndrome(SIRS).
Tumescentinfiltration(TI)drugdeliveryinvolvessubcutaneousinfiltrationrelativelylargevolumes(1to2litersormore)ofarelativelydilutesolutionofepinephrine(≤1mg)inaliterofeither0.9%physiologicsalineorasimilarbalancedsaltsolutionsuchaslactatedRinger’ssolution.Fromapharmacokineticperspective,adilutetumescentinfiltration(TI)Solutionfunctionsasadrugdeliveryvehicle.Tumescentinfiltration(TI)drugdeliveryisamodeofdrugdeliverythathasapharmacokineticprofiledistinctfromintravenous(IV),intramuscular(IM),oral(PO)ortranscutaneousdelivery.
WhenaTISolutionisusedasavehicletodeliverlidocainesubcutaneouslywehaveTIsolution+Lidocaine=tumescentlidocaineanesthesia(TLA).
Further,whenanantibioticisaddedtoaTLAsolution,TISolution+Lidocaine+Antibiotic,theresultisatumescentanestheticantibioticdelivery(TAAD)solution.
TAADdrugdeliveryovercomestwocommontypesofantibiotictoxicities:total(mg)dose-relatedsystemictoxicityandconcentration-related(mg/L)local-tissuetoxicity.
TIdrugdeliveryprovides1)high,prolonged(12to18hoursormore)localizedsubcutaneousdrugconcentrations,2)slowsteadysystemic(serum)drugdeliveryhavingaconcentration-timeprofilesimilartoaslowconstantIVinfusionand
![Page 3: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/3.jpg)
3
3)apeakserumdrugconcentrationthatissubstantiallylessthanwouldbeexpectedbyroutinedosesgivenbyIVdelivery.TAADhasthepotentialtopreventorovercomeanantibiotic-resistantinfectionofsubcutaneous
tissueusinglessthantheusualtotalmgIVdoseofanantibioticwhileprovidinghighersubcutaneousantibioticconcentrationsthancanbeachievedbyIVdelivery,andsimultaneouslyavoidsystemicantibiotictoxicitybylimitingtherateofsystemicantibioticabsorptionandthusminimizingthepeakantibioticserumconcentration.
Forexample,TAADdeliveryofanaminoglycosideantibiotichasthepotentialtoprovidesubcutaneousantibioticconcentrationsthataresufficientlydilutetoavoidlocaltissuetoxicitywhilesimultaneouslyprovidingsubcutaneousantibioticconcentrationsthataresignificantlyhigherthancanbeachievedbyIVdelivery,withareducedriskofsystemic(earorkidney)toxicity.
Thepresentresearchprotocol,onlyallowstheuseofantibioticsthathaveFDAapproval.CefazolinandmetronidazolehaveFDAapprovalandareknowntobesafeandeffectivewhendeliveredbysubcutaneousinfiltrationasdocumentedbypublishedreportsinpeer-reviewedliterature.AclinicaltrialusingsubcutaneousdeliveryofaTAADsolutioncontainingcefazolinandmetronidazolerequiresDivisionofAnti-InfectiveProducts(DAIP)approvalofaninvestigationalnewdrug(IND)application.
Tumescentdilutionreducesthepotentialforsubcutaneous,concentrationdependenttissuetoxicitywhilesimultaneouslyprovidingsubcutaneousdrugconcentrationsthataresignificantlyhigherthancanbeachievedbyIVoranyothermodeofsystemicdrugdelivery.Forantibiotics,thetherapeuticbenefitsofIVdeliveryaremutedbythefactthatIVdeliveryoftenresultsinsub-therapeuticsubcutaneousantibioticconcentrationsandtheassociatedincreasedriskofdevelopingdrugresistance.Forsomecutaneousinfectionsandforpreventingsurgicalsiteinfections,tumescentinfiltrationdrugdeliveryovercomestheselimitationsofIVdelivery.ScientificGeneralizability
Thisprotocolisnotaclinicaltrialcomparingtheeffectsofdifferentdrugs.Thisclinicaltrialprotocolisdesignedtocomparetwomodesofantibioticdelivery.
Inordertomaximizethegeneralizabilityoftheresultsofthisresearch,theprotocolisdesignedtoaccommodateawidevarietyofclinicalsituationsencounteredinternationally.Theprotocolprovidesfortheinclusionofawidevarietyofpathology,surgicaltechniques,surgeontraining/experience,qualityofsurgicalfacilities,diverselocalhealth,localnutritionandlocaleconomicconditions.Theprotocolspecificallyallowsfortheuseoflocallyavailableantibioticproducts.Individualresearchsiteswillusetheirusualandcustomarysourcesofcefazolin,metronidazole,lidocaine,epinephrine,sodiumbicarbonateandphysiologicsaltsolutions.
Researchsiteswillbeprovidedwithsufficientsupplyofdevices(SubQKaths,tumescentlidocaineanesthesia(TLA)peristalticpumpandtubing)tofacilitateefficientTAADinfiltration.
Forthepurposesofscientificvalidityandgeneralizability,thisresearchintentionallydoesnotrestrictthechoiceofgenericantibiotictothatofasinglespecifiedmanufacturer.Thisprotocolexplicitlyallowstheuseofanygenericversionoftheantibiotic,irrespectiveofthemanufacturer.ThisprotocolalsoallowsTAADofanantibioticthatisonlyavailableasabranded(non-generic)drug.
Insomecases,theprincipalinvestigator(PI)willsupplyindividualresearchsitesinmedicallyindigentcommunitieswithaTAADDrugKitcontainingantibiotics,lidocainewithepinephrine,sodiumbicarbonateand1literbagsofabalancedsaltsolution.
Forthepurposeofstatisticalanalysisandvalidity,foranygivensubject,thesameantibiotic(s)willbeusedforbothTAADandIVAD.
Withinanyindividualresearchsite,itispreferredthattheantibioticformulation,sourceandbrandwillbestandardizedandinvariant,subjecttocontinuedavailabilityoftheantibiotic.
![Page 4: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/4.jpg)
4
“Off-Label”AspectsofTumescentDrugDeliveryTheuseofTAADinvolves:1)subcutaneousantibioticdeliverywhichis“off-label”formostFDA-approvedantibiotics,2)unapproveddrugformulations(moredilutetumescentanaesthesiaantibioticdelivery(TAAD)solution3)newunapproved(28mg/kg)recommendedmaximumdosagesfortumescentlidocaine.PrimaryandSecondaryEndPoints
ThisprotocolisdesignedtoprospectivelycollectdatatoevaluatetheefficacyandsafetyoftheTAADmodeofsubcutaneousantibioticdelivery.
Thisprotocolisdesignedtoprospectivelycollectobservationaldatatoevaluatethesafetyandefficacyofthedevices(HKSubQKath,HKtumescentinfiltrationtubingandHKperistaltictumescentinfiltrationpumps)usedforsubcutaneoustumescentinfiltrationofTAADsolutions.
Theprimaryend-pointistheincidenceofsurgicalsiteinfections(SSI).TheprotocolcomparesTAAD+IVADwithIVADalonewithrespectto:1)theincidenceofSSI,2)theincidenceofpost-operativevenousthromboembolism(VTE)and3)theincidenceofsepsis(pathogen-relatedordamage-related).Theprotocolalsorecordsdevice-relatedincidenceofadverseevents.ThedevicesusedforTAADincludeanewsingleusesubcutaneousinfiltrationcannula(HKSubQKath)forthetumescentdrugdelivery,tumescentperistalticpumpsandtumescentinfiltrationtubing.Definitions:Tumescentanesthesiaantibioticdelivery(TAAD)isdefinedasthesubcutaneousinfiltrationofadilutesolutionofantibiotic(s)inasolutionoftumescentlidocaineanesthesia(TLA).TLAconsistsofadilutesolutionoflidocaine(≤1gm/L),epinephrine(≤1mg/L)andsodiumbicarbonate(10mEq/L)in0.9%physiologicsalineorlactatedRinger’ssolution.OurestimatedmaximalsafedosageofTLAlidocaineis28mg/kgwithoutliposuction.
WehypothesizethatTAADtogetherwithintravenousantibioticdelivery(IVAD)willsignificantlyreducetheincidenceofsurgicalsiteinfections(SSI).ThePrincipalaimofthepresentresearchistocomparetwomethodsofantibioticdelivery:1)concomitantTAADandIVAD(TAAD+IVAD)versus2)IVADalone(IVAD),withrespecttothepreventionofSSI.TheIVdosesofantibioticswillbeequalforIVADaloneandforTAAD+IVAD.
ThefocusofthisresearchprojectisonpreventingSSI.Fromastatisticalperspective,studyingSSIamongsubjectswiththehighestriskofSSIminimizessamplesizesrequirementsforagiveneffectsizeandoptimizesstatisticalpower.
ThetargetpopulationsforthepresentclinicaltrialarepatientswhohaveahighriskofSSI.Theseincludepatientsexposedtohigh-risksurgicalprocedures(openabdominalsurgeries,traumasurgeries,burnsurgeries,sternotomy,repairofrecurrentventralhernia)orpatientswhoareobese,havediabetes,areimmune-compromisedorareotherwiseatincreasedriskofSSI.ThesecondaryaimsofthisstudyaretocompareTAAD+IVADvsIVADwithrespecttothe1)preventionofpost-operativevenousthromboembolism(VTE),and2)preventionofpost-operativesepsis(pathogenrelatedortraumarelated).
![Page 5: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/5.jpg)
5
TypeofClinicalTrial:Thisresearchisanopenlabelcontrolledrandomizedclinicaltrial(RCT)comparingtwomodesofantibioticdelivery.Itisnotatrialcomparingantibiotics.
PrimaryOutcomeVariableSurgicalSiteInfection(detectedwithin30daysofsurgery):superficial,deepincisional,organspace.SecondaryOutcomeVariables
1.DiagnosisofVenousThromboembolism(VTE)eitherdeepveinthrombosis(DVT)orPulmonaryembolism(PE)within30daysofsurgery(BinaryData)2.DiagnosisofSepsis,includingsystemicinflammatoryresponsesyndrome(SIRS)3.SafetyofTAADandTLA(incidenceofadverseeventsassociatedwithsubcutaneousantibioticsorlocalanesthesia4.Devicesafetyandefficacy:peristaltictumescentinfiltrationpumpandsubcutaneoustumescentinfiltrationcatheter(SubQKath)
OtherOutcomeVariables1.Post-OpICUadmission(orequivalentunit)andnumberofhoursinICU2.LengthofStay(LOS)inhospitalaftersurgery(hours)3.Timeinpost-operative/post-anesthesiarecoveryunit.4.Timefromarrivalinpost-oprecoverytotimeofambulation).5.Post-OpNarcoticRequirements(totalmgandmg/kg)6.Unexpectedre-admissiontohospital(foranyreason)≤30daysofsurgery(BinaryData)7.GeneralAnesthesiaRequirements(QuantitativeMeasure)8.DiagnosisofC.Difficilecolitis
B.Background:1)RiskofSSIColorectalSurgery.Surgicalsiteinfections(SSIs)areahighprioritytargetofhospitalqualityimprovementefforts1. TheincidenceofSSIdependsonseveralriskfactors.AmongthecommonsurgicalprocedureswiththehighestriskofSSIarecolorectalsurgeries.ThegreatestSSIriskfactorswithrespecttopatients’healthstatusincludeobesity,diabetes,advancedageandcompromisedimmunity.Thedegreeofwoundcontaminationisanotherriskfactor,independentofbaselinehealthstatus.EstimatesofSSIratesinGIsurgeryrangefromlessthan1%to15%forroutineelectiveGIsurgicalprocedurestoapproximately20%to30%forsurgeriesdefinedascontaminatedordirty.2TheincidenceofincisionalSSIincolonperforationwithgeneralizedcontaminationcanbeashighas82%comparedtoa25%incidencewithcolonperforationwithlocalizedcontamination.3TheprevalenceofSSIamongcancerpatientsundergoingelectivecolonandrectalsurgeryremainshigh,23.2and27.6%respectively,despiteevidence-basedpreventiveprocedures.4AmongobesecolectomypatientstheriskofSSIisincreasedby60%.5Lowconcentrationsofantibioticwithinperi-incisionaltissueisasignificantriskfactorforSSIincolorectalsurgery.6
AsignificantpercentageofSSIsbecomesapparentafterhospitaldischarge.7RetrospectivediagnosisofSSIisinaccurate.8Reliableresearchresultsrequiregoodprospectiveclinicalfollow-updatacollectedinatimelymanneratleast30daysaftersurgery.
![Page 6: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/6.jpg)
6
2)StandardofCareforSSIAntibioticProphylaxis.TheCentersforDiseaseControl(CDC)1999consensusguidelinesforSSIantibioticprophylaxisistheworldwidestandardofcare9.TheseguidelinesspecifyrapidbolusIVADofasufficientdoseofappropriateantibiotic(s)initiatedandcompletedwithin60to30minutesofincision,re-administrationofantibioticsifthedurationofsurgeryexceeds4hours,anddiscontinuationofantibioticswithin24hoursafterincision. TherearetwopotentialproblemswiththeCDCguidelines.Compliancewithantibioticguidelinesinclinicalpractice,especiallythetimingofIVAD,isoftennotmuchbetterthan60%1011.Secondly,evenwith100%compliance,theincidenceofSSIcolorectalsurgeryisstillunacceptablyhigh.ItisnowrecognizedthatIVADmaynotalwaysachievesufficientantibioticconcentrationinsubcutaneoustissue.InadequateantibiotictherapyincreasesthelengthofstayandcostincomplicatedSSI12.AmongcolectomypatientsanSSIincreasescostbymorethan$17,000. TAADmayprovidesolutionstotheseproblems.TAADcanbeimplementedatanytimebetween0to4hourspriortoincisionwithsuperiorsubcutaneousantibioticconcentrationscomparedtoIVAD.Amongobesepatients,thecumulativeantibioticexposureorareaunderthecurveoftheantibioticconcentration-timeprofile(AUC)insubcutaneousinterstitialfluidfollowingTAADismorethan100timesthatafterIVAD.133)SubcutaneousBacterialContamination
IntraoperativecontaminationofthesurgicalincisionsiteistheobviouscauseofSSI.AmongcolorectalsurgerypatientswhodevelopSSIthereisan85%incidenceofintraoperativebacterialcontaminationoftheoperativefield14.VirtuallyallbacteriaassociatedwithSSIareextracellularpathogens.ItisaxiomaticthatsuccessfulantibioticprophylaxisofSSIrequiresbactericidalconcentrationsofantibioticwithintheinterstitialfluid(ISF)ofincisedsubcutaneoustissueatthetimeoftheincisionandbactericidalconcentrationoftheantibioticthatpersistoverthedurationofthesurgery.4)SurgeryImpairsSubcutaneousBioavailability
AntibioticconcentrationsintissueatasurgicalincisionsitefollowingIVADcanbesignificantlylessthantheconcentrationinbloodandmaybeinsufficienttopreventthegrowthofbacteria.
Surgeryrelatedhypothermiawithperipheralvasoconstriction,tissuetrauma,desiccation,edema,inflammation,hemorrhage,hypovolemia,reducedcardiacoutput,hypotensionandcapillarythrombosisalldecreaseperfusionattheincisionsiteanddiminishantibiotictransferfrombloodontotheincisionalsurface.Cauteryassociatedchar,necrotictissue,foreignbodies(suturematerial),incision-surfacebloodclots,hematomas,andseromasarenidiforinfection.Thepresenceofavascularsurgicaldetritusdecreaseslocalresistancetobacterialinfectionandincreasestheriskofbacterialbiofilmformation.5)ObesityImpairsSubcutaneousBioavailability
ObesityincreasestheriskofSSI15.ObesityimpairssubcutaneousantibioticbioavailabilityfollowingIVAD.Theareaunderthecurve(AUC)ofdrugconcentrationasafunctionoftimeisameasureoftissueexposuretoadrug.FollowingIVAD,theratioAUCtissue/AUCplasmaisameasureofantibioticpenetrationfrombloodintotissue.Inobesepatientsthisratiois22%thatofnormalsubjects.Inobesepatients,thesubcutaneouspenetrationofcefoxitinafterIVADwaslessthan10%in8of10patients16. Ninetyminutesafterthepre-operativeIVdeliveryof500mgmetronidazoleforintra-abdominalsurgerythemetronidazoleconcentrationinsubcutaneousfatwas36%(4.9µg/g)ofthe13.6µg/mlinserumasmeasuredbyHPLC17.
Inastudyofabdominalwallsurgeries26patientsreceivedmetronidazole500mgintravenouslyduringinductionofanesthesia2hoursbeforesurgery.Plasmaandmusclelevelsofmetronidazolerangedfrom5.7to15.7µg/ml,wellabovetheminimuminhibitoryconcentrationfor90percentof
![Page 7: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/7.jpg)
7
Bacteroidesfragilis.However,metronidazoleconcentrationinsubcutaneousfat(0.6-1.7µg/ml)didnotachievetherapeuticlevels18. TAADisspecificallyintendedfordrugdeliveryintothesubcutaneoustissueofobesepatients.ThethicknessoftheabdominalmidlinesubcutaneousfatisamoreimportantSSIriskfactorthanisbodymassindex(BMI)19.TAADisasimplevariationoftumescentlocalanesthesia(TLA),whichinturnwasoriginallydevelopedspecificallyforpatientswiththickareasofsubcutaneousfattomakeliposuctionasaferandlesspainfulprocedure.6)AntibioticConcentrationafterTAAD
Basedonourclinicalpharmacokineticresearch,atequalantibioticdosages,TAADprovidesantibioticpenetrationinsubcutaneoustissue,whichexceedsthatofIVADbyatleast10-fold.Infact,TAADguaranteesthatthecefazolinandmetronidazoleconcentrationinsubcutaneousfatwillequaltheconcentrationoftheantibioticwithintheinfiltratedtumescentsolutionandthereforecanbeselectedtobeashighasnecessary.
Becausetheefficacyofamodeofantibioticdeliveryisproportionaltothecumulativeantibioticexposurewithinthetargetedtissue,TAADoughttopreventsuperficialSSIfarmoreeffectivelythanIVAD.Incontrast,incontaminatedcolorectalsurgeriesIVantibioticdeliveryismoreeffectivethanTAADforantibioticdeliveryintodeepparenchymaltissues.TAADcannotbereliedupontoproducessufficientlyhighserumconcentrationstopreventsepticemiaoranintra-peritonealabscess.ThusTAAD+IVADoughttobesuperiortoeitherTAADorIVADaloneforcolorectalsurgery.7)TumescentInfiltration TAADinfiltrationinvolvesthesubcutaneousinfiltrationofantibioticsinarelativelylargevolume(typically≥1liter)ofdiluteantibioticsdissolvedinasolutionoftumescentlocalanesthesia(TLA)consistingoflidocaine(<1gm/L),epinephrine(<1mg/L),sodiumbicarbonate(10mEq/L)inphysiologicsaline.PainlessinfiltrationofaliterormoreofTAADsolutionwithoutsignificantsedationorsystemicanalgesiarequirestraining,skillandmedicaldevicesspecificallydesignedforTAAD.TheefficiencyofinfiltratingalargevolumeofTAADsolutionisimprovedwiththeuseofspecializedtumescentinfiltrationcannulas(HKSubQKath),peristalticinfiltrationpump(HKTLAPump)andinfiltrationtubing(HKinfiltrationtubing).8)SubcutaneousMetronidazole
Dilutemetronidazoleissafeforsubcutaneousinfiltration.2021Metronidazoleisavailableasawater-solublepro-drugmetronidazolephosphateforparenteraldeliveryinaniso-osmoticsolutioncontaining500mgmetronidazolein100ml22.
AlthoughtheFDAapprovedlabelingformetronidazoledoesnotmentionsubcutaneousinfiltration,thismodeofdeliveryhasbeenusedwithsuccess.Instate-runhospitalsinIndia,appendicitisisoftenassociatedwithpre-existingmalnutritionandanemia,latepresentation,septicemiaandgrossperitonealcontamination,whichleadtoaveryhighwoundinfectionrate.Inastudyinvolving60patientsundergoingexploratorylaparotomyforperforationperitonitiswithpyoperitoneum,allpatientsreceivedprophylacticIVantibiotics.TheresultingSSIratewas66.6%(20/30)withsalineirrigationoftheincisionsiteversus26.6%(8/30)withsubcutaneousinfiltrationofmetronidazole(P<0.01).Therewerenoadversedrugreactionsattributabletosubcutaneousinfiltrationofmetronidazole23. TAAD-metronidazoleinfiltrationinvolvesthesubcutaneousinfiltrationofarelativelylargevolumeoftumescentmetronidazole(approximately500mg/bagofTAADsolution,andupto2bagsobesepatients).
![Page 8: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/8.jpg)
8
9)SubcutaneousCefazolin Subcutaneousdeliveryofdilutecefazolinisrecognizedasasafeprocedure.24Forsomesurgeonsitiscommonpractice,toinjectcefazolinintoperi-incisionaltissuesortosprinklecefazolinpowderdirectlyontoacutsurfaceofaskinincisionattheendofthesurgicalprocedure.Although”off-label”,thisprocedureisconsideredsafe,butprobablyinefficientgiventhatthebacterialcontaminationhasalreadyoccurredatthetimeofantibioticdelivery. TheFDA–approvedcefazolinpackage-insertstatesthatcefazolinisindicatedforIVorIMdelivery.Thereisnodiscussionregardingtheindicationorcontraindicationforsubcutaneousdelivery.Whenthecefazolinpackageinsertwaswrittenintheearly1970’s,subcutaneousdeliverywasnotdiscussed.Thegoalofantibioticdeliverywastoachieverapidsystemicabsorption.IVandIMdeliveryyieldfasterandmorecompletesystemicabsorption.However,thegoalofTAADinSSIprophylaxisbydirectsubcutaneousinjectionispreciselytoachievetheslowestsystemicabsorptionwiththehighestandmostprolongedlocaltissueconcentrationsofcefazolin. 10)TAADBenefits
TheantibioticsolutionforTAADproducesanintenselocalvasoconstriction,delayedsystemicantibioticabsorption,andprolongedantibioticexposurewithinsubcutaneousinterstitialfluid. WithTAADthelargevolumeofantibioticsolutionbothincreaseslocalinterstitialpressureandactsasasubcutaneousreservoirofantibioticwhichtogetherprovideacontinuousflowofantibioticsolutionfromthesurroundinghyper-hydratedtumescentinterstitialspaceontotheincisionalwoundsurface.
Biofilmscanformdirectlyontraumatizeddesiccatedadiposetissue25.Theeliminationofincisionalsurfacetissuedesiccationphysicallypreventsbacterialadhesiontowoundsurfaceandbiofilmformation.Theoozeoftumescentantibioticfluidfromthecutsurfaceofthewoundiscontinuoushoursafterinfiltration.Thisoozingdrainageisbeneficialinthatitdeliversaconstantflowantibioticinexceptionallyhighclinicalconcentrationontotheincisionsurfacethuspreventingtissuedesiccationandreducingtheriskofinfectionandbiofilmformation262728.
LidocaineisknowntobebactericidalthustheTLAcomponentofTAADmaybebactericidal.ItisremarkablethattheincidenceofSSIassociatedwithsimplemicro-cannulaliposuctiontotallybytumescentlocalanesthesia,whenperformedcautiouslybywell-trainedsurgeons,isessentiallyzero.2930
ThecombinationoflidocaineandepinephrinewithinaTAADsolutionproducesprofoundintra-operativelocalanesthesiaandprolonged(approximately12hoursormore)ofpost-operativeanalgesia.ThusTAADcanbeexpectedtodecreaserequirementsofgeneralanestheticagentsandpost-operativenarcoticanalgesicsandalsofacilitateearlierpost-operativeambulation. 11)TAADMayReduceThromboembolismandBloodViscosity
Theleadingcauseofdeathassociatedwithliposuctionundergeneralanesthesiaispulmonaryembolism31.Incontrast,theincidenceofvenousthromboembolismfollowingtumescentliposuctiontotallybylocalanesthesiaisvirtuallyzero.32Thisremarkabledichotomymightbeexplainedbytheantiplateletactivityoflidocaineintumescentlocalanesthesia(TLA).Itisknownthatlidocaineinhibitsplateletfunction3334.Thereisevidencethatlidocainemayreducetheriskofpost-operativethromboembolism353637.Ourdatafromanon-goingclinicaltrialamongliposuctionpatientssuggeststhatin-vivosystemicplateletfunctionissignificantlyreducedafterinfiltrationofTLAandtheplateletinhibitionpersistsinthepostoperativeperiod38.Withtumescentliposuctiontotallybylocalanesthesia,wehaveobservedthatthereisnodifferencebetweenpreoperativeandpostoperativeplateletcount.
TLAcontainsbothlidocaineandepinephrine.Lidocaineinhibitsplateletactivation.Epinephrinestimulatesplateletactivation.Lidocaineisacapillaryvasodilator.Epinephrineisacapillaryvasoconstrictor.Extensiveworldwideclinicalobservationinvolvingmillionsoftumescentliposuction
![Page 9: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/9.jpg)
9
surgeriesaccomplishedtotallybylocalanesthesiasuggeststhatepinephrinevasoconstrictionoutweighslidocainevasodilation,andlidocaineplateletinhibitionoutweighsepinephrineplateletactivation.
Amongcolorectalsurgerypatients,obesity,diabetes,andcancerincreasetheriskofbothSSIandvenousthromboembolism(VTE).OnestudyfoundthatamongcolorectalsurgerypatientswithulcerativecolitistheriskofDVTwas7.4%39.Ingeneral,colorectalsurgerypatientshaveariskofVTEof1.6%to2.4%.404142.TAADmayreducetheriskofVTE.AnotherstudyfoundthatcolorectalsurgeryforcancerhadariskofVTEashighas16%43.
TLAreducescutaneousandsubcutaneousincisionsitebleeding.TheprofoundlocalizedsubcutaneouscapillaryvasoconstrictioninducedbythelargevolumeofverydiluteepinephrineinaTLAsolutionreducesbothsurgicalbleedingandtheincidenceofhematoma.Priortotheuseoftumescentlocalanesthesia,theliposuctionaspirateundergeneralanesthesiacontained15to30percentbloodandroutinelyrequiredautologousbloodtransfusion44.Incontrast,withtumescentliposuctiontotallybylocalanesthesia,thispercentagetotalbloodintheaspirateisapproximately1to2percent.45
Therearenorandomizedclinicaltrialswhichhavetestedthehypothesisthattumescentlidocainemaysignificantlyreducetheeffectofpostoperativethromboembolismamonghigh-riskpatientsaftermajorsurgery.Inthepresentmulticenterrandomizedclinicaltrial,theoccurrenceofpost-operativedeepveinthrombosisorpulmonaryembolismwillbeanimportantsecondaryoutcomevariable.12)TAADInfiltration:Timing&Technique
ThetimingofTAADisnotascriticalasisthetimingofIVantibioticdelivery.CurrentSSIprophylaxisguidelinesmandatea30minutewindowforIVAD(within30to60minutesbeforeincision)inordertooptimizesubcutaneousantibioticconcentrationatthetimeofincision.Ifdeliveredtooearlyperi-incisionalinterstitialfluid(ISF)concentrationsofantibioticwillhavedeclinedconcomitantlywiththeexponentialdecreaseofserumconcentrationsafterbolusIVAD.IfIVADisdonetoolatethentherewillbeinsufficienttimeforantibiotictobetransferredintotheincisionsiteISFbeforeincisionaltraumaandbacterialcontaminationoccur46474849.
Compliancewithrecommendeddosingschedulesforprophylacticantibioticsincolorectalsurgeryislessthanoptimal.Becauseofcompetingworkflowdemandsinabusyoperatingroom,this30minutetargetcanbemissed40%ofthetime50.
TAADhasthepotentialtorelaxthistime-constraintbydeliveringalong-lastinghighconcentrationofantibioticintosubcutaneoustissuehoursbeforethepatiententerstheoperatingroom.Highsubcutaneousinterstitialfluidantibioticconcentrationspersistforatleast12hoursormoreafterinfiltration.WhenTAADisfollowedbyIVAD,theresultingsubcutaneousandsystemicantibioticconcentrationsaremorelikelytobesufficient,evenifIVADisonlydonewithinminutesbeforeincision.
TAADispreferablydonebeforeenteringtheoperatingroom(OR).TAADinfiltrationcanbedoneineitherapatient’shospitalroomorapre-oppreparationareaunderminimalsedation.Aphysician,aregisterednurseoraphysicianassistantcandotheinfiltrationofTAADsolutionusingtumescentinfiltrationcannulas(HKSubQKath),peristalticinfiltrationpump(HKKTP)andinfiltrationtubing(HKKIP-IIinfiltrationtubing). Becausethepatientisawakewithminimalsedation,minimizingpatientdiscomfortduringinfiltrationisapriority.Painlesstumescentinfiltrationisnotdifficulttoachieve,especiallyinobesepatients,butdoesrequiregentlenessandattentiontodetail. Fromapatientperspective,tumescentinfiltrationfeelsoddbutitisusuallynotregardedas“painful”.Alargemajorityofpatientsrequirenoancillarysedationduringtumescentinfiltration.Oralclonidine(0.1mg)isaneffectiveanxiolyticthatminimizesthechronotropiceffectsofepinephrine.Clonidineiswithheldifthebloodpressureislessthan100/60orpulseislessthan60.Orallorazepam(1mg),withorwithoutclonidine,isalsoeffectiveforpatientswhoareanxiousaboutneedles.Rarelyis
![Page 10: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/10.jpg)
10
midazolam(2mgIMorIV)required.Atropine(0.4mgIVorIM)canbegivenbeforeinfiltrationtopreventsyncopeforpatientswhohaveanyhistoryofvaso-vagalsyncopeornear-syncope.. WhenTAADiscompletedbeforeenteringtheoperatingroom(OR),theinfiltrationprocessdoesnotinterferewiththeORwork-flownordoesitprolongthetotaltimeintheOR.Alternatively,TAADinfiltrationcanbeperformedundergeneralanesthesia.WhenTAADisdoneintheORtheinfiltrationproceduremayconsumeexpensiveoperating-roomtime,addtothelogisticburdenofabusyoperatingroomstaffanddelaytheincision.Detumescence
Detumescence,animportantaspectofTAAD,istheprocessbywhichthetumescenttissuegraduallybecomeslessswollenoveranhourormorefollowingcompletionoftumescentinfiltration.Afterdetumescence,boththegrossappearanceoftheincisedfatandtheeaseofsurgicalmanipulationbecomemorenormal.Infiltratingasub-optimalvolumeoftumescentsolutioncanreducethetimerequiredfordetumescence.However,anyvolumereductionoreliminationofthelidocaineandepinephrinecomponentsinaTAADsolutionislikelytoadverselyaffectthedurationandefficacyoftheantibacterial,antiplateletandpostoperativeanalgesiceffectsofTAAD5152.iii. CriteriaforSubjectSelectionA.NumberofSubjects
Assuminga14%incidenceofSSI,andconsideringa50%reductionintheriskofSSIwithTAADasaclinicallysignificantimprovement(effectsize=50%)oursamplesizeanalysisestimatesthatapproximately330to660subjectswillberequiredtoachieveastatisticalpowerof0.8(Weusedagroupsequentialstatisticalanalysiswithoneintermediatestoppingpoint.Seestatisticalanalysisforsamplesizeestimatesandpoweranalysis).
B.GenderofSubjectsThisstudywillinvolvebothmalesandfemales.
C.AgeofSubjects:Participatingvolunteerpatientsmustbeatleast18yearsold.PediatricpatientswillonlybeenrolledwithFDAINDapproval.
D.RacialandEthnicOriginThereisnorestrictiononparticipationwithrespecttoracialorethnicorigin.
E.InclusionCriteria(Eligibilitycriteriaforparticipationasaresearchsubjectinclude:1.Subjectsgreaterthan18yearsofagescheduledforsurgicalproceduresconsideredtohaveahighriskforasurgicalsiteinfection(SSI)suchas1)secondaryrepairofaventralhernia,2)openbariatricsurgery,3)openabdominalcolorectalsurgery,4)traumasurgery,5)burnsurgeryor6)sternotomy.2.Patientsoughttohaveoneofthefollowingriskfactorsforsurgicalsiteinfection:emergencysurgery,obesity,diabetesmellitus,cancersurgery,beimmune-compromisedorotherwisebeatanincreasedriskforSSI,orbeinamedicallyindigentenvironmentwheresurgicalaseptictechniqueissuboptimal3.Onlyadultswillparticipateasresearchsubjects,unlessthereisspecificFDAapprovaltoenrollpersonslessthan18yearsofage.4.Thisstudywillinvolvebothmalesandfemales5.PatientsinASA(AmericanSocietyofAnesthesiology)class(IorIIorIIIorIV)willbeincluded.6.Foreachpatient,thewoundclassification,ASAclassification,traumaandburnclassificationwillbecarefullyrecorded.Abdominalwoundclassifications:Clean-Contaminated,Contaminated,orDirtyareeligibletoparticipate.7.Patientsmustbeappropriatelyscreenedfortheproposedsurgery.
![Page 11: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/11.jpg)
11
F.ChoiceofAntibioticsThisisnotaclinicaltrialofantibiotics;ratherthisisaclinicaltrialcomparingtwomodesof
antibioticdelivery.Eachindividualresearchsitemustconsistentlyusethesameantibiotics.Allresearchsitesareencouragedtousecefazolinaloneorbothcefazolinandmetronidazolefor
TAADandIVantibioticdelivery.ForTAAD,individualresearchsiteswillhavetheoptiontousecefazolinaloneorbothcefazolin
andmetronidazole.WithappropriateFDAandIRBclearance,anindividualresearchsitemayuseawater-solubleantibiotic,otherthancefazolinormetronidazole,forTAAD.Suchanantibioticmustnothaveanyknownriskofcausingirritationortissuetoxicitywithsubcutaneousinjection.OtherantibioticsthathavebeenclearedbytheFDAforsubcutaneousinfiltrationmaybeusedinTAAD.
ForIVAD,anindividualresearchsitemustconsistentlyusethesameantibioticcombination.Thepreferredcombinationsarecefazolinaloneorcefazolinwithmetronidazole.IfanantibioticotherthancefazolinandmetronidazoleisusedforIVADalone,thenthecompatibilityoftheantibioticcombinationmustbewellestablishedandpre-approvedbytheFDA.G.PatientStratificationandMatching
ForeverypatienttheASAclassification,woundcontaminationclassification,degreeoftraumaordegreeofburnwillberecorded.Thismulticenterclinicaltrialisspecificallydesignedtobeinclusiveofdifferentsurgicalprocedures.ThisRCTdesignwillaccommodatealargerangeofresearchsitesandsurgicalproceduresandimprovethegeneralizabilityofresults. Thefollowingclassificationofpatientcharacteristicsandsurgicalprocedureswillberecorded 1.Immunocompromisedandcancerpatients
2.Obesepatients,3.Diabetics,4.Emergencyoperations,asdesignatedbythesurgeon,willbeincludedonlywiththeappropriateapprovaloftheinstitutionalIRBatforindividualresearchsites.Emergencycaseswillbeclassifiedtogetherwithotheremergencypatients.
Inordertofacilitatemultivariateanalysisandminimizevariance,thestatusofeachpatientwithrespecttoimmunosuppression,cancer,obesity,diabetesandemergencysurgery,willberecorded.H.ExclusionCriteria:Potentialsubjectswillbeexcludedbecauseofanyofthefollowing: 1.Proceduresinvolvingonlysimpleostomyclosures
2.Knownallergytocefazolinormetronidazoleoranantibioticpreferredandroutinelyusedbythesurgeon3.Personslessthan18yearsold,unlessthereisspecificFDAapprovaltoincludepersons<18years.4.EmergencyoperationasdesignatedbythesurgeonwillbeincludedonlywiththeappropriateapprovalbytheinstitutionalIRBatanindividualresearchsite5.Pregnantorbreast-feedingwomenareexcluded.6.Aknownbleeding/hemorrhagic/thromboticdisorderisexclusionaryunlessthereisawrittenclearancechart-noteorclearanceletterfromaprimarycarephysicianorhematologist7.Significantpsychiatricproblemswhichmightimpairabilitytogivetrulyinformedconsentorwhichmayimpairfollow-upcommunicationwiththesurgeonandstaff8.Clinicallysignificantcardiacarrhythmiasareexclusionaryunlessthereisawrittenclearancechart-noteorclearanceletterfromacardiologist9.Heart/liver/kidneydisease,neuropsychiatricdiseaseclassifyingpatientas≥ASAV10.Majorconcomitantinfectionssuchaspneumoniaorsepsis
![Page 12: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/12.jpg)
12
11.Innon-emergencysurgery,pre-existingactivebacterialskininfectionatthetimeofthesurgicalincision;however,pre-existingbacterialinfectionsarenotexclusionaryinburnortraumapatients.12.Foreignmaterialintheincisionthatcannotberemoved13.Recentsystemicantimicrobialtherapy14.Clinicallysignificantrenalimpairmentoracreatinineclearance<30mL/min.
I.VulnerableSubjectsareexcluded1.Pregnantwomen2.Nursinghomeresidents,orotherinstitutionalizedpersonswhoarenotfullyalert,notcognizantorandnotabletogiveinformedconsentarenoteligibletoparticipateasaresearchsubject3.Children<18yearsofage,unlessthereisexplicitFDAapprovalofparticipationofpediatricpatients.
iv. MethodsandProceduresA.DefinitionsofTechnicalTerms,DegreeofObesity:
1.Obesity:BMI≥30to402.MorbidObesity:BMI≥40to503.SuperMorbidObesity≥50
B.SurgicalWoundClassification:DefinitionofSSIissubdividedintothreesubsets.�SuperficialIncisionalSSIisaninfectionwithin30daysofsurgeryinvolvingskinorsubcutaneoustissue�DeepIncisionalSSIisaninfectionwithin30daysaftersurgerywithoutanimplantor1yearifanimplantisleftinplaceandtheinfectionappearstoberelatedtothesurgeryandtheincisioninvolvesfasciaandmusclelayers�Organ/SpaceSSIisaninfectionoccurringwithin30daysofsurgerywithoutanimplantor1yearifanimplantisleftinplaceandtheinfectionappearstoberelatedtothesurgeryandtheinfectioninvolvesanyorgansorspacesopenedandmanipulatedduringthesurgery
ThefollowingcriteriaforadiagnosisofSSSarelistedinCDCGuidelineforPreventionofSurgicalSiteInfection,1999.GuidelineforPreventionofSurgicalSiteInfection,1999.www.cdc.gov/ncidod/dhqp/pdf/guidelines/SSI.pdfCRITERIAFORDEFININGASURGICALSITEINFECTION(SSI)SuperficialIncisionalSSI:� Infectionoccurswithin30daysaftertheoperation&�infectioninvolvesonlyskinorsubcutaneoustissueoftheincisionandatleastoneofthefollowing:1.Purulentdrainage,withorwithoutlaboratoryconfirmation,fromthesuperficialincision.2.Organismsisolatedfromanasepticallyobtainedcultureoffluidortissuefromthesuperficialincision.3.Atleastoneofthefollowingsignsorsymptomsofinfection:painortenderness,localizedswelling,redness,orheatandsuperficialincisionisdeliberatelyopenedbysurgeon,unlessincisionisculture-negative.4.DiagnosisofsuperficialincisionalSSIbythesurgeonorattendingphysician.DonotreportthefollowingconditionsasSSI:1.Stitchabscess(minimalinflammationanddischargeconfinedtothepointsofsuturepenetration).2.Infectionofanepisiotomyornewborncircumcisionsite.3.Infectedburnwound.4.IncisionalSSIthatextendsintothefascialandmusclelayers(seedeepincisionalSSI).
![Page 13: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/13.jpg)
13
DeepIncisionalSSI� Infectionoccurswithin30daysaftertheoperationifnoimplantisleftinplaceor�within1yearifimplantisinplace&theinfectionappearsrelatedtothesurgeryand�infectioninvolvesdeepsofttissues(e.g.,fascialandmuscle)oftheincisionandatleastoneofthefollowing:1.Purulentdrainagefromthedeepincisionbutnotfromtheorgan/spacecomponentofthesurgicalsite.2.Adeepincisionspontaneouslydehiscesorisdeliberatelyopenedbyasurgeonwhenthepatienthasatleastoneofthefollowingsignsorsymptoms:fever(>38ºC),localizedpain,ortenderness,unlesssiteisculture-negative.3.Anabscessorotherevidenceofinfectioninvolvingthedeepincisionisfoundondirectexamination,duringreoperation,orbyhistopathologicorradiologicexamination.4.DiagnosisofadeepincisionalSSIbyasurgeonorattendingphysician.Notes:1.ReportinfectionthatinvolvesbothsuperficialanddeepincisionsitesasdeepincisionalSSI.2.Reportanorgan/spaceSSIthatdrainsthroughtheincisionasadeepincisionalSSI.Organ/SpaceSSI�Infectionoccurswithin30daysaftertheoperationifnoimplantisleftinplaceor�within1yearifimplantisinplace&infectionappearsrelatedtotheoperationand�infectioninvolvesanypartoftheanatomy(e.g.,organsorspaces),otherthantheincision,whichwasopenedormanipulatedduringanoperationandatleastoneofthefollowing:1.Purulentdrainagefromadrainthatisplacedthroughastabwound‡intotheorgan/space.2.Organismsisolatedfromanasepticallyobtainedcultureoffluidortissueintheorgan/space.3.Anabscessorotherevidenceofinfectioninvolvingtheorgan/spacethatisfoundondirectexamination,duringreoperation,orbyhistopathologicorradiologicexamination.4.Diagnosisofanorgan/spaceSSIbyasurgeonorattendingphysician.C.FormulationofTAADSolution:
1.One-literbagofphysiologic0.9%salineassolvent2.Lidocaine1gmandEpinephrine1mgin100ml3.Sodiumbicarbonate10mEqin10ml4.Cefazolin,1gmofpowderedcefazolinperbagofTAADsolution,dissolvedin10mlofsalineobtainedfromthe1Lbagofphysiologicsaline.MaximumdoseofcefazolinbyTAADis2gm.5.Metronidazole,500mgperbagofTAADsolution,wheremetronidazoleisavailableas500mgin100mlandtotalTAADdosenottoexceed1000mg.6.IndividualresearchsitesmayopttoroutinelysubstituteoneormorespecifiedantibioticsforIVantibioticdelivery,insteadofcefazolinandmetronidazole,butonlywithFDAandIRBclearance.
7.MethodofTAADSolutionFormulation(PreparationofthemixtureoftheTAADsolution):
![Page 14: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/14.jpg)
14
a.Thepreparationandmixtureofthetumescentantibioticdelivery(TAAD)solutionshouldbedonewithinlessthan4hoursoftheinitiationofthesubcutaneoustumescentinfiltration.TAADsolutioncanbestoredfor4hoursatroomtemperatureandfor24hoursifrefrigerated.b.OnlyalicensedprofessionalwhohasreceivedtrainingandinstructioninthepreparationandmixingoftheTAADshouldmixandpreparetheTAADsolution.c.DuringthepreparationandmixingoftheTAADsolutionnooneshouldengageinconversationorinanywaydistractthepersonwhoispreparingtheTAADsolution.d.AseachcomponentoftheTAADsolutionisaddedtothe1literbagofTAADsolution,thepersonwhoismixingandpreparingtheTAADsolutionshouldaudiblyandclearlycall-outthenameofthecomponentbeingaddedandcheck-offthecomponentfromthelistofcomponentsorderedfortheTAADsolution.e.TheTAADsolutionshouldnotbepreparedwithoutlegiblesignedorderswrittenbyaphysician,physician’sassistantornurse-practitioner.f.ThecomponentsofeachbagofTAADsolution(oradrugco-kitcontainingallthenecessaryingredientsforpreparingaTAADsolution)willincludethefollowingitems:☐1literbagof0.9%physiologicsaline(sodiumchloride) ☐1gramoflidocaineand1milligramofepinephrinein100ml(two50mlbottles)of1%lidocaineand
epinephrine1:100,000,(orone50mlbottleof2%lidocainewithepinephrine1:50,000).☐10milliequivalentsofsodiumbicarbonatein10mlof8.4%sodiumbicarbonate ☐1000mgvialofcefazolinpowder ☐500mgofmetronidazoleina100mlbagofsolution☐Eitherasterilea30mlsyringeandan18gaugeneedle☐Twoadhesivesafetylabelsstating,“SubcutaneousTumescentLidocaine,NOTforIV”☐Onelabelindicatingthenameofthepatient,thenameofthephysicianwhowrotetheorderfortheTAADsolution,thenameofthepersonwhopreparedthebagofTAADsolution,alistofthedrugcontentsofthebag,thedateandtimeofpreparation.g.EachbagofTAADsolutionshouldbepreparedonacleansurfaceasfollows:1.Applyonesafetylabeltoeachsideofthe1literbagofsalineUsingthesyringeandhypodermicneedle:2.ThemaximumcapacityoftheIVbagmayvarydependingonthemanufacturer.Inordertoaccommodatetheadditional210mloffluid(lidocaine100ml,metronidazole100ml&NaBicarb10ml)thatwillbeaddedtothe1000mlbagofsalinewhenpreparingtheTAADsolution,itmaybenecessaryremovesomevolumesalinebeforeinjectingthelidocaineandmetronidazole.3.Transfer100mlof1%lidocainewithepinephrine1:100,000intotheIVbag4.Transfer10mlof8.4%sodiumbicarbonateintotheIVbag5.Aspirate10mlofsolutionfromtheIVbagintothesyringeandinjectitintothevialcontainingthe1000mg=1gmoflyophilizedcefazolinpowder.Shakethevialofcefazolintopromotedissolutionofthecefazolinpowder.Allowthevialtostandforaminuteortwowhilethecefazolinpowderbecomes
![Page 15: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/15.jpg)
15
completelydissolved.Aspiratethe10mlofdissolvedcefazolinintothesyringeandinjectitintotheIVbagofsaline.6.Usingthesamesterilesyringeandneedle,transferthecontentsofthe100mlbagofmetronidazolesolution(500mg)intotheofIVbagofsolution.7.ApplythelabellistingthenamesofthedrugsandthenameofthecliniciantothebagofTAADsolution.8.StorethenewlymixedbagofTAADsolutionatroom-temperatureinasecureenvironment(forupto4hours)untilreadyforsubcutaneousinfiltration.Ifthetumescentinfiltrationisdelayedbeyond4hoursaftermixingtheTAADsolution,theTAADbagcanberefrigeratedandstoredforupto24hours.
D.MinimumVolumeofTAADInfiltration:
ThevolumeofTAADsolutiontobeusedinthisTAADclinicaltrialis1bagto2bags.Anaverageadultcaneasilybegivenatleast1literofTAADsolution.Forthisrandomizedclinicaltrial(RCT),the1000mlistheminimalvolumeofTAADsolutionforSSIprevention.ThevolumeofTAADsolutiontobeusedisaclinicaldecisiontobemadebythesurgeonoranesthesiologist.Asmallervolumecanbeinfiltratedatthesurgeon’sdiscretion,especiallyinthincancerpatientswhohavelittlesubcutaneousfat.IfthevolumeofTAADsolutionistoosmall,theremaybenobenefittoTAAD.Obesepatientsoughttobegiven2litersofTAADsolution.ThetotalvolumeofTAADsolutionandtheformulationoftheTAADsolutionmustberecorded.InsufficientvolumeofTAADwillexcludethesubjectfromthisRCT.
E.TumescentLidocaineAnesthesia:Tumescentlidocainelocalanesthesiaisamethodofregionallocalanesthesia.Forthepresentresearchthemaximumdosageoftumescentlidocainewillnotexceed28mg/kg,withorwithoutgeneralanesthesia(GA).Aprevious,WIRB-approvedphaseIclinicaltrialhasestablishedthattheestimatedriskofexceeding6mgoflidocaineperliterofserumatadosageof28mg/kgoflidocaineinatumescentsolutionislessthan1per5,000,000(KleinJA,JeskeDR.EstimatedMaximalSafeDosagesofTumescentLidocaine.AnesthAnalg.2016;122:1350-9).TheFDAhasnoscientificdatarelatingtotherecommendedmaximumsafedosageoflidocaineforinfiltrationlocalanesthesia(basedonaFreedomofInformationActinquiry).TLAhasbeenwidelyusedsince1987fortumescentliposuction.GuidelinespublishedbytheAmericanSocietyofPlasticSurgeryandtheAmericanSocietyforDermatologicSurgeryspecify35mg/kgto55mg/kgfortherecommendedmaximumsafedosageoftumescentlidocaineforliposuction.
F.MethodandDevicesforTAADInfiltration.1.TumescentInfiltrationCannulas:HKSurgicaltumescentinfiltrationcathetersorcannulaswillbeusedforinfiltrationofTAADsolution.Twotypesoftumescentinfiltrationcannulasareavailable:reusablestainlesssteeltumescentinfiltrationcannulas(HKMontyinfiltrationcannulas)orasingle-usedisposablesterileplasticcatheter(HKSubQKath).NodevicewillbeusedwithoutFDA510(k)clearanceorinvestigativedeviceexemption(IDE)approval.2.TumescentInfiltrationPump:EitherananalogHKSurgicalanalogperistalticinfiltrationpump(HKKIPII)oranHKSurgicaldigitalinfiltrationpump(HKKTP).BothpumpshaveFDA510(k)clearance.3.Disposablesingle-usesteriletumescentinfiltration-pumptubingsuppliedbyHKSurgical.
G.ApproximateNumberofSubjectsMulticenterCenterTrial:approximately330to660(Groupsequentialanalysiswithoneintermediatestoppingpointwillbeused)forastatisticalpowerof0.8.
H.PrimaryOutcomeVariable:DiagnosisofSSIwithin30daysofsurgery(BinaryData).SurgicalsiteinfectionisdefinedbytheCDCcriteria(seeivBabove).
![Page 16: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/16.jpg)
16
I.SecondaryOutcomeVariables:1.DiagnosisofVenousThromboembolism(VTE)includingdeepveinthrombosis(DVT)orpulmonaryembolism(PE)within30daysofsurgery.ThedefinitionanddiagnosticcriteriaforVTEandroutinemethodsofVTEprophylaxisusedbyeachresearchsitewillberecorded.ThemethodofdiagnosisofVTEmayvaryamongresearchsites.Butwithinanygivensitethediagnosticmethodsshouldbeconsistentlythesame.2.SafetyofTAAD:Incidenceofadverseeventsassociatedwith
a)DilutesubcutaneousTAADsolutionb)InfiltrationofTAADsolution
Thefollowingsafetyassessmentchecklistwillbecompletedbetween24to36hoursafterTAADinfiltration:Indicate(below)ifanyofthefollowingtumescent-infiltrationsitesignsandsymptomsappearwithinthefirst24hoursaftersurgery:TAADADVERSEEVENTSQUESTIONNAIREProblems:Check-OffOneAnswerper
Problem
Grade1None
Grade2
Mild/Moderate
Grade3Severe
Grade4
Life-Threatening
1.DERMATOLOGIC
Bruising None AtTAADsite Excessive,Unusual NA
Petechiae None
AtTAADsite Generalized,Widespread
NA
Pruritus None
AtTAADsite Generalized,Widespread
NA
Induration,Swelling None
AtTAADsite Generalized,Widespread
PainorTenderness None AtTAADsite Excessive,Unusual NA
Rash,Erythema None AtTAADsite Diffuse NA
Rash,Eczematous None AtTAADsite Diffuse NA
Rash,Maculopapular
None AtTAADsite Diffuse
NA
Rash,Bullous None
AtTAADsite Stevens-Johnson ToxicEpidermalNecrolysis
Cellulitis None
OnlyPOAntibiotics IVAntibiotics
Sepsis,TissueNecrosis
NecrotizingFasciitis None
NA LimitedtoTAADSite
Sepsis,WidespreadNecrosis
![Page 17: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/17.jpg)
17
2.CARDIOVASCULAR
ThrombosisorPulmonaryEmbolism(PE)
NoSymptoms
Symptoms&Nointerventionindicated
Symptoms & Intervention indicated
Life-threatening PE
Arrhythmia
NoSymptoms&Nointervention
NoSymptoms&Nourgentintervention
Symptoms&Nourgentintervention
Life-ThreateningArrhythmia
Hypertension ≤160/100 160/100to180/110
>180/110 MalignantHypertension
Hypotension NoSymptoms
RequiresPOfluids
IVfluidsneeded Shock
Cardiac Ischemia/MI NA NA
+TestsorSymptoms
UnstableorAcuteMI
Congestive Heart failure (CHF)
NoSymptoms
Symptomsuponexertion
Symptomsatrest,NeedsOxygen
LifeThreatening,UrgentIntervention
Vasovagal Reaction
None Nearsyncope Syncope
Hemorrhage NA Notransfusion Transfusion≤2unitsPRBC
>2unitsPackedRBC(PRBC)
3.ALLERGICREACTIONS
Anaphylaxis None NA GradualOnset ImmediateOnset
Angioedema
None
NoAirwayInvolvement
MildAirwayInvolvementNoInterventionRequired
ThreatenedCompleteAirwayObstruction
4.GI
diarrhea NoneorMinimal
≥3to6overbaseline
≥7stoolsin24hours
Massive,Life-threatening
nausea
Transient
Persistent,Decreasedoralintake24-48hrs
MinimalIntake≥24-48hrs,RequiresIVFluids
Life-Threatening,HypotensiveShock
![Page 18: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/18.jpg)
18
Vomiting
NonetoMinimal,AbletoEat
Frequent,MildDehydration
Persistent,RequiresIVFluids
Life-Threatening,HypotensiveShock
Pancreatitis None
Mild Moderate SevereorLife-Threatening
5.MUSCULOSKELETAL
Arthralgia,Arthritis None
Mild,NoInterferencewithActivities
Moderate,InterferswithNormalActivities
Severe,UnabletodoSelf-Care
Myalgia,MusclePains
None
Mild,NoInterferencewithActivities
Moderate,InterferswithNormalActivities
Severe,UnabletodoSelf-Care
6.NEUROLOGIC
AlteredMentalStatus
None
MildLethargy,Somnolence
Confusion,MemoryImpairment
Delirium,Obtundation,Coma
Ataxia None
Detectable,NormalActivities
Moderate,InterferswithNormalActivities
Severe,UnabletodoSelf-Care
Headache None
Mild,Doesn'tInterferwithActivity
Moderate,InterferswithActivity
Severe,UnabletodoSelf-Care
WeaknessNeuromuscular
None
Mild,Doesn'tInterferwithActivity
Moderate,InterferswithActivity
Severe,UnabletodoSelf-Care,orAffectsBreathing
Seizures None NA 1to3Seizures ProlongedSeizures,RefractorytoTreatment
Syncope
None
Mild,Vaso-VagalNearSyncope
LossofConsciousness,NoTreatmentRequired
LossofConsciousness,RequiresTreatment
7.RESPIRATORY
AcuteBronchospam
None
MildSymptoms,NotreamentRequires
Moderate,RequiresTreatment
Severe,PossiblyRequiresIntubation
![Page 19: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/19.jpg)
19
Dyspnea None
DyspneaonExertion DyspneaatRest
RespiratoryFailure,RequiresIntubation
9.SENSORY
HearingLoss None
Mild,NoTreatmentRequired
Moderate,InterfereswithActivity
ProfoundBilateralHearingLoss
Tinnitus None
Mild,NoTreatmentRequired
Moderate,InterfereswithActivity
Severe,PreventsNormalActivities
Vertigo None
Mild,NoTreatmentRequired
Moderate,InterfereswithActivity
Severe,PreventsNormalActivities
10.SYSTEMIC
Chills None
Mild,NoTreatmentRequired
Moderate,InterfereswithActivity
Severe,PreventsNormalActivities
FatigueMalaise None
Mild,NoTreatmentRequired
Moderate,InterfereswithActivity
Severe,PreventsNormalActivities
Fever ≤38.6 38.6-39.3 39.4-39.9 ≥40
LABORATORYVALUES:(ComparedtoBaselinePriortoTAAD)
ALTSGPT
WithinNormalLimitsorBorderline NA
SignificantElevation
SevereHepatitis
ASTSGOT
WithinNormalLimitsorBorderline NA
SignificantElevation
SevereHepatitis
Amylase
WithinNormalLimitsorBorderline NA
SignificantElevation
LifeThreateningPancreatitis
HEMATOLOGIC
WBC
WithinNormalLimitsor
NA SevereLeukopenia
LifeThreateningLeukopenia
![Page 20: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/20.jpg)
20
Borderline
AbsoluteNeutrophilCount
WithinNormalLimitsorBorderline NA
SevereLeukopenia
LifeThreateningLeukopenia
PlateletCount
WithinNormalLimitsorBorderline NA
SevereThrombocytopenia
LifeThreateningThrombocytopenia
AENotOtherwiseSpecified
3.SafetyandefficacyofTLAsolution4.Safetyandefficacyofsubcutaneousinfiltrationcatheter5.Safetyandefficacyofperistaltictumescentinfiltrationpumpfor
J.OtherOutcomeVariables1.ICUadmission(orequivalentunit)andnumberofhoursinICU2.LengthofStay(LOS)inhospitalaftersurgery(hours)3.Timeinpost-operative/post-anesthesiarecoveryunit.4.Timefromarrivalinpost-oprecoverytotimeofambulation).5.Post-OpNarcoticRequirements(totalmgandmg/kg)6.Unexpectedre-admissiontohospital(foranyreason)≤30daysofsurgery(BinaryData)7.GeneralAnesthesiaRequirements(QuantitativeMeasure)8.DiagnosisofSepsis9.Diagnosisofsystemicinflammatoryresponsesyndrome(SIRS)10.DiagnosisofC.Difficilecolitis
K.IndependentPredictorVariables:Thefollowingisalistofdataitemstobecollectedpriorto,duringoraftersurgery.
1.PatientRoutineDemographicData:Identification,Age,Sex,Height,Weight,BMI,Race2.Surgeon(s):Name,age,yearsofpost-residencyexperience,boardcertificationorpost-graduateresidencystatus3.Surgeon’schoiceofantibioticstobegivenbyTAADandbyIVAD4.Surgeon’sapproximateannulvolumeofsurgicalproceduressimilartothesurgeriesperformedinthepresentresearch.5.PrimarySurgicalDiagnosis
6.SurgicalProcedure(OpenColonRectalSurgery,OpenBariatricSurgery,etc.)7.TotalDosagesofallGeneralAnestheticAgents8.Useofandtypeofsubcutaneoussutures9.Materialusedforseromuscularsuturing10.AmericanSocietyofAnesthesiologists(ASA)status.11.ListofSignificantMedicalProblemsandCo-Morbidities(Endocrine/Diabetes,Hypertension,Cardiovascular,Pulmonary,Renal,GI,etc)12.ConcurrentDrugs&Dosages13.ImmuneStatus(Diabetesmellitus,Chemotherapy,Radiationtherapy,Corticosteroidorotherimmunosuppressivetherapy,HIVstatus,etc)
![Page 21: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/21.jpg)
21
14.Steroid(glucocorticoids)name,dosageanddurationofuse15.Immunosuppressantdruguse(non-steroidal):name,dosagedurationofuse16.Drug(s)knowntosignificantlyaffecthemostasis(plateletfunctioninhibitors,aspirin,ibuprofen,clopidogrel,heparin,etc).17.DrugAllergies18.OccurrenceofConcomitantantibioticIVADprophylaxis(appropriate/adequateorinappropriate/inadequateaccordingtoCDCguidelines)19.Takinganydrug(s)knowntointerferewiththemetabolismoflidocaine,cefazolinormetronidazoleortoadverselyinteractwiththesedrugs(Erythromycin,Clarithromycin,ketoconazole,fluconazole,sertraline(Zoloft),ciprofloxacin.20.Historyofradiationtherapyinvolvingtheareaneartheproposedincisionsite21.Intraoperativehypotensionorhypertension22.Intraoperativehypothermia23.Operativetime:incision-to-close24.AbdominalWoundClass:Clean,Clean-Contaminated,Contaminated,Dirty(SeeAppendix)25.Numberoftimesperdaythatincisionsiteiswashedwithsoapandwater26.Thicknessofmidlineabdominalsubcutaneousfat(estimatedpriortotumescentinfiltration)measuredbyultrasoundifavailable.27.HistoryofSmoking
28.Anyconditionwithsignificantriskofsurgicalsitewoundinfections29.ListofPriorSurgeries30.Pre-existingorConcurrentInfections(cutaneous,urinary,pneumoniaareexclusionary)31.ListofmeasuresforpreventingVTEactuallyemployedforeachindividualsubject
32.PsychologicalDiagnoses,majordepression,psychosis,anxietydisorder.33.Presenceanddurationofprolongedwounddrainage
34.TimeofcompletionoftheIVADwillbeclassifiedintothefollowinggroups: a)IVADcompletedmorethan60minutespriortoincision b)IVADcompletedmorethan30minutesandlessthan60minutespriortoincision c)IVADcompletedbeforeincisionandlessthan30minutespriortoincision d)IVADafterincisionandduringthesurgery e)IVADafterthesurgicalclosure f)NoIVADL.DataMonitoringCommittee:DatawillbemonitoredbytheClinicalTrialsStatisticsCollaboratory,DepartmentofStatistics,UniversityofCalifornia,Riverside,CA
•DanielJeskePhD,Chair,DepartmentofStatistics,UCR•ClinicalTrialCoordinator:TobedeterminedAdditionalmembersoftheDataMonitoringCommitteemayincludeselectedphysiciansaswellasgraduatestudentsandfacultyintheUCRMedicalSchoolortheUCRDepartmentofStatistics,UniversityofCalifornia,Riverside,willcomposethedatamonitoringcommitteetoassurethesafetyofthesubjects.Thestatisticaldesignofthistrialincludesperiodicgroupsequentialanalysis(withonestoppingpoint)toallowearlyterminationofthestudyintheeventofearlystagestatisticalsignificance.
M.ClinicalOversightCommittee:•TherewillbeanIndependentClinicalOversiteCommitteethatwillmonitortheclinicaldata,protocolcomplianceandallreportsofadverseoutcomes.•AgroupofTrialSitePrincipalInvestigatorswillperiodicallyreviewtheclinicaldata,protocolcomplianceandanyreportedadverseoutcomesandconferwiththeDataMonitoringCommitteeandtheClinicalOversiteCommittee.
![Page 22: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/22.jpg)
22
•AteachclinicalresearchsitetheSub-PrincipalInvestigatorwillberesponsibleforassuringthesafetyofthesubjectsatthatsite.
N.Thisisacontrolledopenlabelrandomizedclinicaltrial(RCT):•ThistrialisarandomizedclinicaltrialoftheTumescentAntibioticDeliveryplusIntravenousAntibioticDelivery(TAAD+IVAD)versusIVADalone.•Becauseofthenatureoftumescentinfiltration,itisnotpossibletomaskthetreatmentassignment.ThepatientandtheclinicianwhodeliverstheTAADinfiltrationcannotbe“blinded”tothetreatmentassignment.•Itispreferredthattheanother(different)clinicianwilldotheclinicalevaluationslookingforsurgicalsiteinfections(SSA).
O.StatisticalAnalysis,PowerCalculationsandSamplesSizeEstimationDanielJeskePhDandJoyceFu,DepartmentofStatistics,UniversityofCalifornia,Riversidehelpeddesignthestatisticalanalysisforthepresentclinicalinvestigation.Wewillusegroupsequentialanalysiswithonestoppingpoints.Usingbalancedtreatmentallocation,assumingtheincidenceofsurgicalsiteinfectioninthetargetedpopulationis0.14andananticipatedeffectsizeof50percentatalevelofsignificance(alpha)of0.05andapowerof0.8,theestimatedsamplesizefortheTAADRCTiseither330(atfirststoppingpointwith165control=IVADand165treatment=IVAD+TAAD)or660patients.SeeTAADSampleSizeEstimate,attachedasanappendix.
P.TreatmentAssignmentandRandomizationOnlyafterhavingobtainedappropriateinformedconsentfromthepatientwillthepatientberandomlyassignedtoatreatment.AllpatientswillreceiveIVADofcefazolin.Thetiming(30to60minutespriortosurgicalincision)andmg/kgdosageofIVADantibioticwillconformtoacceptedCDCGuidelinesforSSIProphylaxisandthehospitalpolicies.
Inthisstudy,patientswillberandomlyassignedtooneof2treatmentgroups:
•Controlgroup(IVAD)willreceiveIVADonly[50%ofpatients]•Treatmentgroup(TAAD+IVAD)willreceivebothTAADandIVAD[50%ofpatients]
Thefollowingmethodofbalancedrandomassignmentforanopen-labeldesignassuresthattheintendedproportionofpatientswillbeassignedtotherespectivetreatmentgroups.Forexample,atagivenresearchsite,iftherehavebeen4npatientsenrolledwithinasetofmatchedpatients,then2npatientswillbeassignedtoreceivecontroltreatmentIVADand2npatientsassignedtoreceivetreatmentTAAD+IVAD.
Balancedrandomizationwillbephysicallyaccomplishedbyassignmentdeterminedbyflippingafaircoin.Thepersonwhoperformsthefollowingrandomizationtaskshouldnotbeasurgeonoramemberofthesurgicalteam.Specifically,bywayofexample,ifaresearchsiteexpectstoenroll24patients,then1)Sequentiallylabel24envelopsand24cards(5x7inch)from1to24.2)Placeeachcardinsidethecorrespondinglynumberedenvelope.3)Separatetheenvelops-cardsintogroupsoffoureach:{1,2,3,4},{5,6,7,8},…,{21,22,23,24}.4)Selectasetof4envelops,andremoveacardfromoneoftheenvelopes.5)Flipthecoin:
a)IfthecoinshowsheadsthenwriteIVADonthechosencardb)IfthecoinshowstailswriteIVAD+TLDonthecard
![Page 23: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/23.jpg)
23
c)After2patientshavebeenassignedtoIVADthentheremainingcard(s)willbeassignedtoIVAD+TAAD.d)Thus,witheachgroupof4cards,exactly2cardswillberandomlyassignedtoIVADand2cardswillberandomlyassignedtoIVAD+TAAD.
6)Foldeachofthecardsonce,withthewrittenassignmentobscuredfromview,thenreplaceeachcardintoitscorrespondingenvelopeandsealallfourenvelops.7)Repeatthissequenceuntilall24cards-envelopshavebeengivenatreatmentassignment.8)Arrangetheenvelopsintonumericalorder9)Onthedayofasubject’ssurgery,afterthepatienthassignedtheinformedconsentandthepatienthasbeenscreenedanddeterminedtoconformtoalloftheinclusioncriteria,butnoneoftheexclusioncriteria,thenextenvelopinthesequence(theenvelophavingthelowestnumber)isassignedtothepatient.(Ingeneral,treatmentassignmentshouldnotbemademorethan12hourspriortosurgeryinordertoavoidpossibleconfusionifthesurgeryweretobecancelled.10)Theassignedenvelopisopenedbyaclinician,thetreatmentindicatedonthecardisassignedtothepatientandtheappropriateordersforIVADaloneorIVAD+TAADwillbeformallywrittenonthehospital’sroutinepre-operativeorderform(s).11)IfthecardindicatesTAAD+IVADthenanassignedresearch-teammemberwillpersonallysuperviseandwitnessthepreparationoftheTAADsolutionorpersonallymixthebag(s)ofTAADsolution.EachbagofTAADsolutionwillbelabeled(frontandback)withHKSafetyLabels,whichstate“NOTforIVUSE”12)Thepatient’snameiswrittenonthecardandthecardisfiledinasecure(locked)locationforfuturereference.13)Thepatient’sname,dateofrandomizationandtreatmentassignmentarerecordedonaconfidentialmasterlistcontainingthenamesofallsubjectsandcorrespondingtreatmentassignments.14)ThemasterlistofpatientsandindividualtreatmentassignmentswillbeemailedtothePIandtheSafetymonitoringcommitteeaftereverysubjecthasbeenenteredintotheclinicaltrial.15)Alternatively,dependingonfuturefunding,wemightinstituteaniPadbasedrandomizationprocesswithfeaturessimilartothosedescribedabove.
Q.FormulationandDosageofTAADSolution:TAADcanconsistofcefazolinandmetronidazoleinasolutionoftumescentlidocaineanesthesia(TLA).EachliterbagofTLAsolutionconsistsoflidocaine,epinephrine,sodiumbicarbonateaddedtoa1literbagof0.9%salineorlactatedRinger’ssolutionorHartman’ssolution.EachbagofTAADsolutionwillcontain:Cefazolin1gmasdesiccatedpowderdissolvedinsalinefromthebag0.9%salineorabalancedsaltsolution.Metronidazole500mg/100mlLidocaine1000mg&Epinephrine1mgin100mloflidocaine(1%)withepinephrine(1;100,000)SodiumBicarbonate10mEqin10mlofsodiumbicarbonate(8.4%)PhysiologicSaline0.9%1000mlTotalvolume=1210ml
R.TAADDosages&Delivery:Withgeneralanesthesia,inpatientswhodonothavesignificantcardiac,hepaticorrenalimpairment,themaximumlidocainemg/kgdosagewillnotexceed28mg/kg,which,ina70kgpatient,isapproximately2gmoflidocainein2bagsofTAADsolution.Patientswhodohavesignificantcardiac,hepaticorrenalimpairmentareexcludedfromparticipatinginthisTAADRCT.
![Page 24: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/24.jpg)
24
Withoutoutgeneralanesthesia,themaximumlidocainemg/kgdosagewillnotexceed28mg/kg,which,ina70kgpatient,isapproximately2gmoflidocainein2bagsofTAADsolution.
ThetotalvolumeofTAADsolutionwillprobablyrangefrom1210mlinsmallpatients
andupto2420mlinobesepatients;inotherwords,approximately1to2bagsofTAADsolution.TheminimumvolumeofTAADsolution(inverythinpatients)is500ml.ThedeterminationoftheactualvolumeofTAADsolutiontobeinfiltratedismadebythesurgeonoranesthesiologist.Theinitialstudieswillallowamorepreciseestimateoftherangeofvolumes.ThetargetedareaofsubcutaneoustissuetobeinfiltratedwithTAADsolutionshouldincludetheanticipatedsurgicalincisionlineplusthesurroundingborderareahavingamarginof10to20cmoneachsideoftheincisionsite.Fortheabdomen,thetotalwidthofsubcutaneoustumescence(theambitofTAADinfiltration)willbeabout20to40cm.
TotalTAADantibioticmgdosageswillconformtocommunitystandardsofcare,whichmayexceedantiquatedpackageinsertlabeling.Recentpublicationshaveshownthatincertainclinicalsituations(e.g.obesity)thebioavailability,peakconcentration(Cmax)andTimeAboveMIC(T>MIC)ofantibioticsinsubcutaneoustissuearesub-therapeutic.Thus,recentpeer-reviewedevidencebasedmgdoserecommendationstypicallyexceedcefazolinproductlabeling.
DeliveryofTAADsolutionbysubcutaneousinfiltrationwillbeaccomplishedusingHKSurgicalperistalticinfiltrationpump,peristalticinfiltrationtubing,andSubQKaths(disposable,singleuse,subcutaneousinfiltrationcannulas).AlldeviceswillhaveFDA510(k)clearanceorFDAinvestigativedeviceexemption(IDE).
InstructionsforPreparingTAADSolutionwillbeincludedintheresearchmanual.InstructionsforTumescentInfiltrationwillbeincludedintheresearchmanual.S.ResearchDesign:DrugDeliveryTimingandTechnique
•IVADtiming:ForIVADalone(withoutTAAD)theIVADinfusionshouldbecompletedwithin30to60minutespriortosurgicalskinincision.TheactualtimefromstarttocompletionofIVADwillberecorded.•TAADtimingandtechnique:infiltrationtobecompletedlessthan4hourspriortoskinincision.ForIVAD+TAAD,theIVADwillbeinitiatedandcompletedbeforetheincision.TheactualtimefromstarttocompletionofIVADwillberecorded.•SubcutaneousinfiltrationwillbeaccomplishedbyusingHKtumescentinfiltrationcannulasandHKperistaltictumescentinfiltrationpumpandinfiltrationpumptubing.AlldeviceswillhaveFDAclearance/approval.InfiltrationprocedurewillbecarriedoutwitheitherthepatientawakewithminimalornosedationorwithIVorIMsedationorwhilethepatientisundergeneralanesthesia.Thepatientandsurgeonwilldeterminewhichoftheseinfiltrationoptionswillbeused.
T.CriteriaforDiagnosisofSSI,VTE&SepsisCriteriaforDiagnosisofSSIwillbedefinedaccordingtothecriteriaoftheCentersforDiseaseControlupdatedandpublishedAugust201153.AdmittedlytheCDCdefinitioniscomplexandrequiressometrainingforeffectiveuse.SeesectionivBabove,orequivalentlywww.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf.
“SignificantSSI”isdefinedasaSSIthatrequirestheuseofadditionalhealthcareresources.OnlysignificantSSIwillbeconsideredinthefinalstatisticalanalysis.Thiswillavoid
![Page 25: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/25.jpg)
25
confoundingeffectofincluding“false-positive”resultsassociatedwithtrivialornormalincision-siteinflammationortumescentfluiddrainagefromanincisionsite. WerecognizethattheCDCdefinitionofSSIincludeselementsthatcannoteasilybestandardizedsuchasaclinicaldiagnosisofSSIbyaclinician,ortheclinicaldecisiontosubmitwoundswabsforbacterialculture.CriteriaandMethodsforDiagnosisofVTEtobedeterminedandstandardizedbyeachresearchsite.CriteriaandMethodsforDiagnosisofSepsistobedeterminedandstandardizedbyeachresearchsite.
U.MethodstoReducePotentialforBiasinOutcomeDetermination:Therewillbetwoseparatetypesofquestionnaires.SSI,VTE,SepsisQuestionnaires:Post-operativequestionnairesconcernedwithdeterminingtheoccurrenceofSSI,VTE,Sepsiswillnotcontainquestionsthatwouldallowtheinterviewertodetermineinferorguesswhichmodeofantibioticdeliverywasassignedtothesubject.Thepersonwhoconductstheinterviewwillbeinstructednottodiscussthemodeofantibioticdelivery.ModeofDeliverySideEffectsQuestionnaire:Therewillbetwoquestionnairesregardingpossiblesideeffectsoftumescentantibioticdelivery(TAAD).Onequestionnairewillbeconcernedwithpossibleacutelocaltissuetoxicityandacutesystemictoxicity,whichwillbeadministered18to36hoursaftersurgery.Thesecondquestionnairewillbea“dischargequestionnaire”tobecompletedonthedayofdischargefromthehospitalorclinic.Differentpersonswillbeassignedtoadministerthetwodifferentquestionnaires.Thepersonswhoadministerwillbe“SSI,VTE,Sepsis”questionnaireswillbeinstructedtonotdiscusstheirresultswillthepersonswhoadministerthe“SideEffects”questionnaire.V.Methodsofpost-dischargesurveillanceforSSIorVTE
Fundamentaltotheprospectivedesignofthisclinicaltrialisafeasible,valid,reliableandstandardizedmeansofdefininganddetectingSSIand/orVTEduringhospitalizationandafterdischarge.PatientswhohaveanSSIorVTEafterdischargewillbeidentifiedbyoneofthefollowingPost-DischargeSurvey(PDS)techniques:1.Follow-upclinicalinterviewandquestionnaire.Theinterviewandquestionnairewillbeconductedbyadesignatedhealthcareprofessional30to45daysaftersurgery.BecauseoflogisticalandeconomicconstraintsadditionalPDSmethodsmayinclude:2.Post-dischargequestionnaireforpatient(telephone,textmessage,onlinewebsitesurvey,mailoremail)3.CardsgiventopatientstofacilitatenotificationofhealthcarepersonnelofaSSIorVTEbymail,emailortelephonecall4.Medicalrecordchartreviewwiththeintenttoidentify
a.Readmissionsb.Additionalsurgicalproceduresc.Positiveculturesobtainedduringhospitalizationorafterdischarged.Reviewofoperatinglogstosearchforevidenceofasurgicalrevisione.ReviewofRadiology/Ultrasounddiagnostictests
5.DataCollectionGuidelinesanddatacollectionformswillbespecifiedintheresearchers’handbook.6.DataMonitoringGuidelineswillbespecifiedintheresearchers’handbook.7.MonitoringforAdverseEvents:inadditiontosearchforevidenceofSSIandVTE,clinicalobservationwilldocumentanyevidenceofrash,subcutaneoustissueinflammationortoxicity,
![Page 26: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/26.jpg)
26
dyspnea,heartpalpations,irregularheartrate,chestpain,headaches,focalweakness,confusion,gastrointestinalirritation,diarrhea,hematemesis,blacktarrystoolsandotheradverseevents.
LocationandDescriptionofSurgicalFacilitiesAllsurgerieswillbeperformedinsurgicalfacilitiesorhospitalsthathavebeenaccreditedbythelocalorstategovernment.Specificresearchsitesandsurgicalfacilitiesremaintobedetermined.
DurationofSubjects’ResearchParticipationPre-Op:Forresearchsubjectsinthisclinicaltrialthereshouldbeminimalextratime-commitmentbeforethedayofsurgery.Pre-operativehistory,physicalexamination,diagnosticevaluationandclearanceprocedurespriortothesurgeryshouldnotrequirethepatienttospendanyextratimepriortothesurgery.Post-Op:Afterthesurgery,theresearchstaffwillcontactthepatientforoneortwobriefpostoperativefollow-upconversationsandquestionnaires.Thirtyto45daysaftersurgery,allsubjectswillberequiredtoparticipateinafollow-upinterviewandquestionnaire,eitherin-personorbytelephone.Ifasubjecthasexperiencedapossiblesurgicalsiteinfectionorapossiblepost-operativebloodclotsinthelegsorlungsorsepsisthenafollow-upexaminationmayberequired.
ListofResearchProcedurestobeusedtoaccomplishthespecificaimsoftheproject:1)Subcutaneoustumescentantibioticdelivery(TAAD)2)Clinicalquestionnaires
DataStorageandConfidentiality:Alldataandclinicalrecordswillbestoredinasecuredareaattherespectiveresearchsite.InadditionthedatafromallresearchsiteswillbecollectedbytheDataMonitoringCommitteeandmaintainedinasecurefashion.ConfidentialitywillconformtoHIPAArequirements.
TransitionfromResearchParticipation:Patientresearchparticipationwillendattheconclusionofthe30to45daypost-operativefollow-upperiod,exceptforpossibleroutineclarificationofquestionnaireanswers.Subsequentroutinenon-experimentalclinicalcareforeachpatientwillcontinuewiththepatient’ssurgeonandprimarycarephysicians.
W.Risk/BenefitAssessment
1.RiskCategory:Theriskcategoryforthisresearchprojectisminimal.2.SafetyofTAAD:ThesafetyofeachdrugcomponentwithintheTumescentAntibioticDelivery(TAAD)solutioniswellestablished(SeeReferences).Thesedrugsincludedilutecefazolin,dilutemetronidazole,dilutelidocaine,diluteepinephrine,dilutesodiumbicarbonate,andphysiologic0.9%saline.ThesedrugshavebeenusedforTAADinthepreviousWIRB-approvedresearch.Seethefollowingpeer-reviewedpublicationsofresultsofthisresearch:KleinJA,JeskeDR.EstimatedMaximalSafeDosagesofTumescentLidocaine.AnesthAnalg.2016;122:1350-9.KleinJA,LangmanLJ.Pharmacokineticsofsubcutaneouscefazolinandmetronidazoleinatumescentlidocainesolutionforpreventionofsurgicalsiteinfectionsandbiofilms.PlastReconstrSurgGlobOpen2017;e1351.Therewerenoadverseeventsrelatedtothedrugsorproceduresinthatclinicaltrial.
![Page 27: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/27.jpg)
27
3.Safetyoflidocaineandtumescentlocalanesthesia:ThesafetyofTumescentLidocaineAnesthesia(TLA)iswellestablished.TLAhasbeenusedonmillionsofpatientsandisrecognizedastheworldwidestandardofcareforsafeliposuctiontotallybylocalanesthesia.Eachofthepharmacologicagentsisgenericdrugwithawell-establishedsafetyprofile.TheseincludeLidocaine,Epinephrine,SodiumBicarbonate,andphysiologic0.9%saline.ThesedrugshavebeenusedforTLAinthepreviousWIRB-approvedandnowclosedprotocol(WIRB®Protocol#20050127)entitled:BioavailabilityandAbsorptionKineticsofTumescentLidocaine(clinicaltrials.govNCT00977028).Thatresearchprojectestimatedthat,foraTLAlidocainedosageof28mg/kgwithoutliposuctionandwithoutgeneralanesthesia,theriskofmildlidocainetoxicity(serumlidocaineconcentration≥6μg/ml)is1per5,000,000.Inthepresentclinicaltrialthemaximumdosageoftumescentlidocainewillbe28mg/kgwithoutgeneralanesthesiaand21mg/kgwithgeneralanesthesia.4.SafetyofTumescentInfiltrationTechniqueandDevices:Thetechniquefortumescentinfiltrationiswellestablishedandiscurrentlyusedbythousandsofsurgeonsworldwide.AlldevicestobeusedinthepresentresearchwillhaveFDA510(k)orIDEclearance/approval.5.SafetyofEpinephrine:Thedosagesoftumescentepinephrinethatwillbeusedinthepresentclinicaltrialhavebeenwellestablishedassafeandeffective.Themaximumdosageoftumescentepinephrinetobeusedinthisclinicaltrialisnotexpectedtoproduceanyclinicalproblemsassociatedwithtachycardia.6.SafetyofCefazolinandMetronidazole:Thesafetyofsubcutaneousdeliveryofdilutecefazolinanddilutemetronidazoleiswellestablishedintheliterature,bothforpreventingSSIandforpalliativetreatmentofterminallyillpatients(seereferences).Inthepresentclinicaltrialthemg/kgdosagesofcefazolinandmetronidazolewillconformtocommunitystandardsofcare.
X.PotentialRiskofTAADandTLA:
1)InfiltrationCannula.Therearetwotypesofinfiltrationcannulasthathavebeendesignedforsubcutaneoustumescentinfiltration:1)SubQKathisadisposableover-the-needleplasticcannulaspecificallydesignedforTAADand2)Montyinfiltrationcannulasarestainlesssteelblunttippedcannulas(havingtinyholesdistributeddistallyalong50%to90%ofthecannulalength)thatwereoriginallydesignedforinfiltrationoftumescentlidocaineanesthesiaforlargesurgeriestotallybylocalanesthesia.“Painless”infiltrationofTAADinafullyawakepatientrequiresthebriefuseofasharpneedle(forexample,aspinalneedle)insertedintosubcutaneousfatforinitiatingthetumescentinfiltration.Thereisariskofpunctureofdeepanatomicstructuresassociatedwiththeuseofspinalneedles.Theriskofinjuryfromthisneedleisminimizedbyacarefulinfiltrationtechnique:Theneedleisheldintheclinician’sdominanthandandadvancedparallel(tangential)tothesub-dermalplane,whilethecontralateralhandgentlygraspsandelevatestheskinastheneedleiscarefullyadvancedwiththeneedletipcontinuouslylocatedbetweenthefingerandthumbofthecontralateralhand.Afterthisbriefinitialphaseoftumescentinfiltration,alargergauge(typically18gaugeor16gauge)blunt-tippedMontyinfiltrationcannulaisinsertedintothesubcutaneoustissueandusedforinfiltratingtheremaining90percentormoreoftheTAADsolution.
Y.ProtectionagainstRisk
1)Criteriaforterminatingthestudyinclude:a)Thesurgeondeterminesthatitisunsafe,unethicalorunreasonablethatapatientcontinuetoparticipateintheresearchproject.
![Page 28: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/28.jpg)
28
b)Thepatientdoesnottolerateinfiltrationoftumescentlocalanesthesiabecauseofanxietyordiscomfort.(Asanalternative,thepatientcanbegiventheoptionforthetumescentlocalanesthesiatobeinfiltratedbythesurgeonafterinductionofgeneralanesthesiaandbeforetheincision).
2)Monitoringfortoxicoradversedrugevents:PatientswillbeobservedandquestionedwithrespecttoanysignsorsymptomsofadversereactionstothedrugusedforTAADincludingrash,dyspnea,heartpalpations,irregularheartrate,chestpain,headaches,focalweakness,confusion,gastrointestinalirritation,hematemesis,blacktarrystools.TheriskofanallergicadverseeventwithTAADshouldbenodifferentthanthatassociatedwithIVantibioticdelivery.
Z.PotentialBenefittotheSubject:Thereisnoguaranteethatvolunteersubjectswillreceiveanymedicalbenefitsfrombeinginthisstudy.Thepatientmaybenefitbyhavingadecreasedriskforasurgicalsiteinfectionoravenousthromboembolism.Allpatientswhoparticipateinthisresearchprojectwillroutinelyreceivethe“standardofcare”methodsforpreventingasurgicalsiteinfectionandforpreventingapost-operativebloodclotinalegorlung.Approximately50percentofthevolunteersubjectswillreceiveboththe“standardofcare”intravenous(IVAD)preventivetreatmentsforSSIandanadditionaltreatmentintheformofanantibioticsolutioninjecteddirectlyintothesubcutaneousfattytissuesurroundingthesiteoftheincision(TAAD).IfTAADprovestobeoptimalforpreventingSSIamongpatientshavingGIsurgery,traumasurgeryorburnsurgerythenitislikelyTAADwillalsobebeneficialforfutureuseinotherpatientshavingsimilarorothertypesofsurgeries.
ZZ.AlternativestoParticipation:Personsdonothavetoparticipateinthisstudytohaveanappropriatesurgicalprocedure.Anyprospectivevolunteersubjectmaychoosetohavetheroutine“standardofcare”methodsforpreventingasurgicalsiteinfectionandforpreventingapost-operativebloodclotinalegorlungwithoutparticipatinginthisstudy.
vi. SubjectIdentification,RecruitmentandConsent/AssentA.MethodofSubjectIdentificationandRecruitment:Theprimarymethodofrecruitmentwillinvolveadiscussionbetweentheprospectiveresearchsubjectandthesurgeonorthesurgeon’sstaff.Patientswhoarealreadyscheduledtohaveoneofthetargetedsurgicalprocedureswillbeofferedtheopportunitytoparticipateinthisstudy.Therewillbenopublicadvertisingorpublicrecruiting.B.ProcessofConsent:Eachparticipatingsurgeonorthesurgeon’sdesignatedstaffmember,suchasanotherknowledgeableandexperiencedphysician,physician’sassistantorregisterednurse,willdiscussandobtaininformedconsentfromeverypatientorthepatient’sdesignatedguardianincaseofemergencysurgery.C.SubjectCapacitytoGiveInformedConsent:Allprospectiveadultsubjectsmustbefullycapableofcomprehendingandgivingtheirowninformedconsentor,incaseofemergencysurgery,thepatient’sdesignatedguardianmustbefullycapableofcomprehendingandgivinginformedconsent.D.Subject/RepresentativeComprehension:Allprospectiveadultsubjectsoradesignatedguardianmustbefullycapableofcomprehendingandgivingtheirowninformedconsent.E.DebriefingProcedures:Thisisnotapsychologicalstudy.Theonlyformaldebriefingwillconsistofpost-operativefollow-uptelephonecall(s)toorfromthepatientand/orafreereturnfollow-upoffice
![Page 29: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/29.jpg)
29
visitbythepatienttomeetwiththesurgeonoroneofthesurgeon’sresearchassistants.Allpatientswillhavetheopportunitytomeetpersonallywiththesurgeonbeforeorafterthesurgeryandasoftenasnecessarytodiscussanyquestionsandaddressanyconcernsthatapatientmighthaveregardingthesurgeryortheresearchproject.F.ConsentForms:Todocumentinformedconsent,allsubjectswillsignatleastthreeconsentforms:IRBResearchConsentForm(individualresearchsiteswillhavetheirownIRB-approvedconsentforms),theHIPAAConsentForminadditiontotheresearchsite’sstandardsurgicalconsentform.G.DocumentationofConsent:Patientconsentformswillbeplacedinthepatient’sresearchchart.Thechartwillbekeptinalockedfilingcabinet.H.CosttotheStudySubject:Studysubjectswillpayforthecostoftransportationtovisitthesurgeonforfollow-upvisits.Ifresearchfundingisobtained,thensubjectsmaybeofferedpaymentfortheirtransportationexpensesforfollow-upvisits.Thereisnoextrachargeorextraexpensetothepatients/subjectsforparticipatinginthisresearchproject.Thereisnochargetothepatientforroutinefollow-upvisitswhicharescheduledaspartofthisresearchproject.I.PaymentforParticipation:Volunteersubjectswillnotbepaidforparticipationinthisresearchproject.ResearchsiteswillnotbepaidbythesponsorofthisresearchforparticipationinthisTAADresearch.IndividualresearcherswillnotbepaidbythebythesponsorofthisresearchforparticipationinthisTAADresearch.Criteriafordiagnosisofsurgicalsiteinfection(SSI)&ProtocolguidelinesinperformingtheprimaryassessmentofSSI:
�Duringhospitalization,dailyvisual&physicalexamofincisionsitewillbedone.
�Betweenpost-opdays30to45,patientistobeevaluatedand/orinterviewedand/orpatient’schartwillbereviewed.
Bibliography1FryDE.Surgicalsiteinfectionsandthesurgicalcareimprovementproject(SCIP):evolutionofnationalqualitymeasures.SurgInfect9:579-584,2008.2WickEC,HiroseK,ShoreAD,ClarkJM,GearhartSL,etal.Surgicalsiteinfiectionsandcostinobesepatientsundergoingcolorectalsurgery.ArchSurg146:1068-1072,2011.3WatanabeM1,SuzukiH,NomuraS,MaejimaK,ChiharaN,KomineO,MizutaniS,YoshinoM,UchidaE.Riskfactorsforsurgicalsiteinfectioninemergencycolorectalsurgery:aretrospectiveanalysis.SurgInfect2014;15:256-61.4Serra-AracilX,Garcia-DomingoMI,ParésD,etal.Surgicalsiteinfectioninelectivesurgeryforcoloncanceraftertheapplicationofpreventivemeasures.ArchSurg146:606-612,2011.
![Page 30: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/30.jpg)
30
5WickEC,HiroseK,ShoreAD,ClarkJM,etal.Surgicalsiteinfectionsandcostinobesepatientsundergoingcolorectalsurgery.ArchSurg146:1068-1072,2011.6ZelenitskySA,ArianoRE,HardingGK,SilvermanRE.Antibioticpharmacodynamicsinsurgicalprophylaxis:anassociationbetweenintraoperativeantibioticconcentrationsandefficacy.AntimicrobAgentsChemother.2002;46:3026-30.
7OlsenMA,Chu-OngsakulS,BrandtKE,etal.Hospital-associatedcostsduetosurgicalsiteinfectionafterbreastsurgery.ArchSurg143:53-60,2008.8HedrickTL,SawyerRG,HennessySA,TurrentineFE,FrielCM.Canwedefinesurgicalsiteinfectionaccuratelyincolorectalsurgery?SurgInfect2014;15:372-6.9MangramAJ,HoranTC,PearsonML,SilverLC,JarvisWR.GuidelineforPreventionofSurgicalSiteInfection,1999.CentersforDiseaseControlandPrevention(CDC)HospitalInfectionControlPracticesAdvisoryCommittee.AmJInfectControl.27:97-132,1999.10MeeksDW,LallyKP,CarrickMM,LewDF,etal.Compliancewithguidelinestopreventsurgicalsiteinfections:Assimpleas1-2-3?AmJSurg.201:76-83,2011.11BratzlerDW,HouckPM,RichardsC,etal.Useofantimicrobialprophylaxisformajorsurgery:baselineresultsfromthenationalSurgicalInfectionPreventionProject.ArchSurg140:174-182,2005.12EagyeKJ,KimA,LaohavaleesonS,KutiJL,NicolauDP.Surgicalsiteinfections:doesinadequateantibiotictherapyaffectpatientoutcomes?SurgInfect10:323-31,2009.
13KleinJA,JeskeDR.EstimatedMaximalSafeDosagesofTumescentLidocaine.AnesthAnalg.2016;122:1350-9.14NishikawaK,HanyuuN,YudaM,TanakaY,etal.Howcanwecontrolintraoperativebacterialcontaminationandsurgical-siteinfectionduringananteriorresectionorHartmann's/Miles'operation?JGastrointestSurg.12:1995-2000,2008.15FalagasME,KompotiM.Obesityandinfection.LancetInfectDis6:438-46,2006.16TomaO,SuntrupP,StefanescuA,LondonA,MutchM,KharaschE.PharmacokineticsandTissuePenetrationofCefoxitininObesity:ImplicationsforRiskofSurgicalSiteInfection.AnesthAnalg113:730-737,201117IngoldbyCJ,DeanPH,VowdenP,GilesGR.Inappropriateuseofmetronidazoleingastrointestinalsurgery.AlimentPharmacolTher.3:277-84,1989.18BadiaJM,delaTorreR,FarréM,GayaR,Martínez-RódenasF,SanchoJJ,Sitges-SerraA.Inadequatelevelsofmetronidazoleinsubcutaneousfatafterstandardprophylaxis.BrJSurg.82:479-82,199519LeeJS,TerjimanianMN,TishbergLM,AlawiehAZ,etal.Surgicalsiteinfectionandanalyticmorphometricassessmentofbodycompositioninpatientsundergoingmidlinelaparotomy.JAmCollSurg.213:236-44,2011.
![Page 31: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/31.jpg)
31
20BhargavaP,MehrotraN,KumarA.Woundinfectionaftermetronidazoleinfiltration.TropDoct.2006;36:37-8.21ShubingW,LitianZ.Preventinginfectionoftheincisionafterappendectomybyusingmetronidazolepreoperativelytoinfiltratetissuesattheincision.AmJSurg.1997;174:422-4.22ChoMJ,KurtzRR,LewisC,MachkovechSM,HouserDJ.Metronidazolephosphate--awater-solubleprodrugforparenteralsolutionsofmetronidazole.JPharmSci.71:410-4,1982.23BhargavaP,MehrotraN,KumarA.Woundinfectionaftermetronidazoleinfiltration.TropDoct.36:37-8,2006.DepartmentofSurgery&PediatricSurgery,LadyHardingeMedicalCollege&Assoc.,SmtSuchetaKriplaniHospital,NewDelhi110001,[email protected],BlankI,SeidelW.Peritonealandsubcutaneousadministrationofcefazolinasperioperativeantibioticprophylaxisincolorectaloperations.Prospectiverandomizedcomparativestudyof200patients.LangenbecksArchChir.1996;381:318-22.25SchaberJA,TriffoWJ,SuhSJ,etal.Pseudomonasaeruginosaformsbiofilmsinacuteinfectionindependentofcell-to-cellsignaling.InfectImmun75:3715-3721,2007.26WolcottR,DowdS.Theroleofbiofilms:arewehittingtherighttarget?PlastReconstrSurg127(Suppl):28S-35S,2011.27CostertonJW,DeMeoP.Discussion:Theroleofbiofilms:arewehittingtherighttarget?PlastReconstrSurg127(Suppl):36S-37S,2011.28FreiE,Hodgkiss-HarlowK,RossiPJ,EdmistonCEJr,BandykDF.Microbialpathogenesisofbacterialbiofilms:acausativefactorofvascularsurgicalsiteinfection.VascEndovascularSurg2011(epublishedbeforeprint)29ColdironBM,HealyC,BeneNI.Officesurgeryincidents:WhatsevenyearsofFloridadatashowus.DermSurg2008;34-285-292.30LenhardtM,HomannHH,DaigelerA,etal.Majorandlethalcomplicationsofliposuction:Areviewof72casesinGermanybetween1998and2002.PlastReconstrSurg2008;121:393e-403e.31GrazerFM,deJongRH.Fataloutcomesfromliposuction:censussurveyofcosmeticsurgeons.PlastReconstrSurg105:436-446,2000.32HousmanTS,LawrenceN,MellenBG,etal.Thesafetyofliposuction:resultsofanationalsurvey.DermSurg2002;28:971-978.33NachmiasV,SullenderJ,AschA.Shapeandcytoplasmicfilamentsincontrolandlidocaine-treatedhumanplatelets.Blood50:39-53,1977.
![Page 32: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/32.jpg)
32
34NachmiasVT,SullenderJS,fallonJR.Effectsoflocalanestheticsonhumanplatelets:filopodialsuppressionandendogenousproteolysis.Blood53:63-72,1979.35BorgT,ModigJ.Potentialantithromboticeffectsoflocalanestheticsduetotheirinhibitionofplateletaggregation.ActAnesthesiolScand.29:739-742,198536StewartGJ.Neutrophilsanddeepvenousthrombosis.Haemostasis.23Suppl1:127-40,1993.37HuangGS,LinTC,WangJY,KuCH,HoST,LiCY.LidocaineprimingreducesADP-inducedP-selectinexpressionandplatelet-leukocyteaggregation.ActaAnaesthesiolTaiwan.47:56-61,2009.38KleinJ.Tumescentlidocaineinhibitsin-vivoplateletfunction.(Inpreparation)WIRBProtocol#20102004(TumescentLidocaineEffectsonPlateletFunctionFollowingLiposuctionSurgicalTrauma:AProspectiveControlledDosage-ResponsePhaseIClinicalTrial).39ScarpaM,PilonF,PengoV,etal.Deepvenousthrombosisaftersurgeryforinflammatoryboweldisease:isstandarddoselowmolecularweightheparinprophylaxisenough?WorldJSurg.34:1629-36,2010.40McNallyMP,BurnsCJ.Venousthromboembolicdiseaseincolorectalpatients.ClinColonRectSurg22:34-40,2009.41AminAN,LinJ,ThompsonS,WiederkehrD.Inpatientandoutpatientoccurrenceofdeepveinthrombosisandpulmonaryembolismandthromboprophylaxisfollowingselectedat-risksurgeries.AnnPharmacother.45:1045-52,2011.42SandersonB,HitosK,FletcherJP.Venousthromboembolismfollowingcolorectalsurgeryforsuspectedorconfirmedmalignancy.Thrombosis.Epub2011May26.43StenderMT,NielsenTS,FrøkjaerJB,LarsenTB,Lundbye-ChristensenS,Thorlacius-UssingO.Highpreoperativeprevalenceofdeepvenousthrombosisinpatientswithcolorectalcancer.BrJSurg.94:1100-3,200744CourtissEH,ChoucairRJ,DonelanMB.Large-volumesuctionlipectomy:ananalysisof108patients.PlastReconstrSurg.89:1068-79,1992.45KleinJA.Tumescenttechniqueforlocalanesthesiaimprovessafetyinlargevolumeliposuction.PlastReconstrSurg92:1085-1098,1993.46ButtsJD,WolfordET.Timingofperioperativeantibioticadministration.AORNJ65:109-115,1997.47HawnMT,GraySH,VickCC,etal.Timelyadministrationofprophylacticantibioticsformajorsurgicalprocedures.JAmCollSurg.203:803-811,200648Wong-BeringerA,CorelliRL,SchrockTR,GuglielmoBJ.Influenceoftimingofantibioticadministrationontissueconcentrationsduringsurgery.AmJSurg169:379-381,1995
![Page 33: Title: Tumescent Anesthesia Antibiotic Delivery (TAAD) and ...tumescent.org/wp-content/uploads/170515-Protocol-WIRB-TAAD-.pdf · These include patients exposed to high-risk surgical](https://reader034.vdocuments.us/reader034/viewer/2022050520/5fa3ad4cbbc70736507fce06/html5/thumbnails/33.jpg)
33
49DellingerEPWhatistheidealtimeforadministrationofantimicrobialprophylaxisforasurgicalprocedure?50HoVP,BariePS,SteinSL,etal.Antibioticregimenandthetimingofprophylaxisareimportantforreducingsurgicalsiteinfectionafterelectiveabdominalcolorectalsurgery.SurgInfect12:255-260,2011.51KatzJ,ClarkeH,SeltzerZ.Preventiveanalgesia:quovadimus?AnesthAnalg113:1242-1253,2011.52Pogatzki-ZahnEM,ZahnPK.Frompreemptivetopreventiveanalgesia.CurrOpinAnaesthesiol.19:551-555,2006.53CDCCriteriaandDefinitionsforSSI.AccessedNovember24,2011http://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSIcurrent.pdf